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I. Abbreviations 
 
11β-HSD1:  11β-Hydroxysteroid Dehydrogenase Type 1  
11β-HSD2: 11β-Hydroxysteroid Dehydrogenase Type 2  
17β-HSD3:  17β-Hydroxysteroid Dehydrogenase Type 3  
17β-HSD5:  17β-Hydroxysteroid Dehydrogenase Type 5 
AAS:  Anabolic Androgenic Steroids  
AKR:  Aldo-Keto Reductase 
Androstenedione: ∆4-androstene-3, 17-dione  
AP1:  Activator protein 1 
AR:  Androgen Receptor 
ARE:  Androgen Responsive Elements  
ATF-2:  Activation Transcription Factor 2 (ATF2)  
BMI:  Body Mass Index 
bp:  base pairs  
CI:  Confidence Interval 
CPY:  Cytochrome P450 
Ct:  Cycle Threshold 
CVD:  Cardio Vascular Disease 
DEX:  Dexamethasone  
DHEA:  Dehydroepiandrosterone  
DHEAS:  Dehydroepiandrosterone Sulfate 
DHT:  Dihydrotestosterone 
DMT2:  Diabetes Mellitus Type 2  
DSD:  Disorder of Sex Development  
EIA:  Enzyme Immunoassay 
ELISA:  Enzyme Linked Immunosorbant Assay  
ER:  Estrogen Receptor 
ERK:  Extracellular Signal-Regulated Kinase 
ESI:  Electro Spray Ionisation 
GC:  Gas Chromatography 
GR:  Glucocorticoid Receptor 
H6PDH:  Hexose-6 Phosphate Dehydrogenase  
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HDL:  High Density Lipoprotein  
HSD:  Hydroxysteroid Dehydrogenase 
IKK:  I kappa B-Kinase  
IUPAP:  International Union of Pure and Applied Chemistry 
JNK:  c-Jun N-Terminal Kinase 
LC:  Liquid Chromoatography 
LH:  Luteinizing Hormon 
MAP2K:  MAPK Kinase 
MAP3K:  MAPK Kinase Kinase 
MAPK:  Mitogen Activated Protein Kinase 
MR:  Mineralocorticoid Receptor 
mRNA:  Messenger RNA  
MS/MS:  Tandem Mass Spectometry 
MS:  Mass Spectrometry  
NAD+:  Nicotinamide Adenine Dinucleotide  
NADP:  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH:  Nicotinamide Adenine Dinucleotide Phosphate Hydroxyl 
NR:  Nuclear Receptor 
PBS:  Phosphate Buffered Saline 
PC:  Prostate Cancer 
PR:  Progesterone Receptor 
PSA:  Prostate Specific Antigen 
RA:  Retinoic acid  
RE:  Response Elements 
RIA:  Radioimmunoassay  
RIP:  Receptor Interacting Protein  
rtPCR:  Real Time Polymerase Chain Reaction  
RXR:  Retinoid X Receptor  
S.D.:  Standard Deviation 
S:  Steroid 
SAME:  Syndrome of Apparent Mineralocorticoid Excess 
SDR:   Short Chain Dehydrogenase Reductases    
StAR:  Steroidogenic Acute Regulatory Protein 
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TBT:  Tributyltin 
TF:  Transcription Factor 
TLC:  Thin Layer Chromatography 
TNFR1: Tumor Necrosis Factor Receptor 1  
TNF-α:  Tumor necrosis factor-α  
TPT:  Triphenyltin 
TRADD:  TNFR-Associated Death Domain  
UPLC:  Ultra High Pressure Liquid Chromatography 
WHO:  World Health Organisation 
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1. Summary 
Communication between organs and tissues is predominately controlled by hormones. Hormones 
regulate a vast variety of physiological and behavioural activities, including metabolism, growth and 
development, reproduction, sleep and mood. Steroid hormones are characterized by their sterane 
backbone and are regulated by distinct enzymes which control the balance between their active and 
their inactive forms. It is a common feature of steroid hormones to bind to nuclear receptors in order to 
exert their action. Steroid hormones are classified into five groups, depending on the receptor they 
bind: glucocorticoids, mineralocorticoids, androgens, estrogens and progestogens. Most research 
within the field of steroidogenesis focuses on the receptors, since they play a pivotal role in converting 
the chemical signal from the active steroid hormone into a biological response. The present studies of 
this thesis focus on the enzymes which selectively control and regulate the availability of active ligand 
for receptor binding. The two major enzyme superfamilies responsible for the interconversion of the 
active to the inactive hormones are the aldo-keto-reductases (AKRs) and the short chain 
dehydrogenase/reductases (SDRs), which both belong to the hydroxysteroid dehydrogenases (HSDs). 
Additionally, a smaller family, consisting of the 5α-steroid reductases play distinct roles in androgen 
formation. The balance between the inactive and active steroid hormones within the same class is 
important (e.g. cortisone and cortisol). However, the balance of active steroids from different classes 
(e.g. mineralocorticoids and glucocorticoids) also plays an important role in (patho)physiology. For 
example, glucocorticoids play a role in psychological stress and depression which are risk factors in 
androgen sensitive diseases, such as cancer and male and female infertility. 
The first project described in my thesis investigated the impact of anabolic androgenic steroids (ASS) 
on the enzyme activity of 11β-hydroyxsteroid deydrogenase 2 (11β-HSD2). ASS are known to induce 
cardiovascular complications. The underlying mechanisms remain largely unknown. Using enzyme 
activity assays we observed that fluoxymesterone, a widely used ASS, potently inhibited 11β-HSD2- 
dependent inactivation of cortisol to cortisone. Furthermore, using LC-MS/MS we could show that 
fluoxymesterone is metabolized to 11-oxofluoxymesterone by human 11β-HSD2. Structural modelling 
revealed that the binding modes for fluoxymesterone and cortisol are similar, suggesting that 
fluoxymesterone may act as a competitive inhibitor of 11β-HSD2. No direct modulation of the 
mineralocorticoid receptor (MR) could be observed in transactivation assays. Since cortisol is able to 
potently activate the MR, we suggested that fluoxymesterone-induced inhibition of 11β-HSD2 could 
contribute to cortisol-induced MR activation, leading to electrolyte dysbalance and elevated blood 
pressure and subsequent cardiovascular disease development. The inhibitory potential of ASS in rat 
kidney microsomes and in cells expressing recombinant mouse 11β-HSD2 revealed a much weaker 
inhibition, revealing important species differences. This study unveiled potential pathways involved in 
adverse cardiac outcomes as a result of ASS misuse. It furthermore highlights the importance of 
species differences, especially within the field of steroidogenesis.  
The second study presented in my thesis investigated the pathways involved in the generation and 
metabolism of androgens in Leydig cells. Currently, Leydig cell are needed to investigate the 
androgen axis, thus, their characterisation with respect to this axis is vital. Our investigation in two 
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important Leydig cell lines, the well-established MA-10 cells and the more recently established BLTK-1 
cells, showed that there are marked differences regarding androgen metabolism between these two 
cell lines. Enzyme activity assays showed that 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) 
-dependent formation of testosterone from androstenedione is not the predominant pathway in BLTK-1 
cells. This observation was supported be the low expression of HSD17B3 mRNA in BLTK-1 cells. We 
further investigated the specific pathway by which the BLTK-1 cells degrade androstenedione. Liquid 
chromatography/ mass spectrometry LC-MS/MS measurements confirmed that BLTK-1 cells 
predominately reduce androstenedione to androsterone via the intermediate metabolite, 5α-
androstanedione. This alternative pathway is part of the “back-door” pathway, which ultimately leads to 
the formation of 5α-Dihydrotestosterone (DHT) and which has not been shown before in an 
established cell model. Under stress conditions, cells are able to switch pathways from the well-known 
17β-HSD3-mediated androstenedione reduction to testosterone to the back-door pathway. In addition 
to characterizing the pathways in two different Leydig cell lines, we compared and tested different 
methodologies to specifically quantify androgen metabolites. Our results emphasize that for complex 
steroid matrices, LC-MS/MS measurement is the method of choice. Enzyme immunoassay need to be 
evaluated carefully (since they may show a high cross-reactivity, especially when metabolites of the 
back-door pathways are involved). Tin layer chromatography (TLC) should only be carried in validated 
two-dimensional or even in three-dimensional systems. Our study was able to demonstrate that the 
MA-10 and the BLTLK-1 cells both are valuable models. However, they should be used only for 
investigation a specific pathway.  
In the third study presented in my thesis, we investigated the transcriptional regulation of the 
HSD17B3 promoter. 17β-HSD3 is the key enzyme for testosterone formation of the front-door 
pathway. With the ultimate goal to identify compounds interfering with testosterone formation we 
constructed a MA-10 Leydig cell line stably expressing a 2.8 kilo base sequence of the putative human 
HSD17B3 promoter under the control of a luciferase reporter gene. Using this tool, I carried out two 
projects:  
A) We could show using transactivation assays, that TNF-α strongly activates the HSD17B3 promoter 
via the p38 MAPK pathway. Importantly, this activation could not be reversed by the synthetic 
glucocorticoid dexamethasone. The results from our novel reporter assay were supported both on the 
mRNA-level and by enzyme activity measurements. The key conclusion from this study was the 
identification of a pathway which may link cancer-related inflammation with elevated testosterone 
levels, subsequently contributing to the growth and progression of androgen dependant tumors. 
B) The mechanisms of imposex induction in aquatic organisms are still disputed. Using the screening 
tool described above, we showed that the retinoid X receptor (RXR) ligand 9-cis retinoic acid and 
specific organotins are able to activate the human HSD17B3 promoter. This finding suggests that 
organotins exert pro-androgenic effects. We propose in a future study to address a possible link 
between two established yet controversial theories of imposex onset in aquatic organisms: the 
involvement of RXR and the elevation of testosterone levels. 
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In conclusion, the results presented in this thesis significantly extend our knowledge on the roles of 
SDRs and emphasize the importance of studying pre-rector regulation. Within the complex field of 
steroid measurement, this thesis provides important data and novel information. Further, the 
importance of considering species-specific differences when trying to extrapolate steroidigenic effects 
observed in animal models to humans is underlined. 
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2. Introduction 
2.1 Steroid hormones 
Steroids form a class of organic compounds derived from the hydrocarbon sterane (Cyclopentanoper-
hydrophenanthren). Steroids share a common characteristic structure, consisting of a chain of three 
cyclohexane rings (A-C) and one cyclopentane ring (D) (Figure 1). Steroids are widespread among 
animals, plants and fungi. Their biochemical roles are very diverse. Steroids can act as hormones, 
vitamins, bile acids, plant toxins and others. Synthetic steroids show a strong affinity to bind to nuclear 
receptors and are therefore popular scaffolds for drug research (Gupta et al., 2013). The 
pharmacological applications of steroids cover antibiotic drugs, anticancer drugs, anti-inflammatory 
drugs and others. Furthermore, a large number of doping agents were synthesized from the steroid 
scaffold.  
 
 
 
 
 
 
Figure 1: Steroid structure including numbering according to IUPAC 
http://www.chem.qmul.ac.uk/iupac/steroid/3S01.html 
Steroids acting as hormones are known as steroid hormones. Steroid hormones usually exist in a 
balance between their active and inactive forms. The active form can be produced either by endocrine 
or intracrine actions. Steroid hormones are produced from cholesterol in specific tissues referred to as 
the endocrine glands. In the human body, the major endocrine glands secreting steroid hormones are 
the adrenals and the gonads (ovaries and testes). After secretion, the hormones are delivered via the 
circulation to their specific site of action (Luu-The, 2013). This system of targeting receptors on cells 
distant from the site of hormone production is referred to as the endocrine system.  
In contrast, intracrine tissues are not able to transform cholesterol into active steroid hormones. 
However, intracrine tissues form active steroids from inactive precursors depending on the enzymes 
they express. Inactive precursors are found in the circulation and originate from endocrine glands and 
form a part of a homeostasic feedback system which balances the levels of inactive and active 
hormones in the body (Labrie et al., 1997a; Labrie et al., 1997b; Labrie et al., 1997c).  
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Steroid hormones exert their action by binding to their cognate nuclear receptor (NR). Once the steroid 
(S) is bound to a NR, the receptor dimerizes, translocates into the nucleus where it directly binds to 
specific response elements (RE) on the DNA, which initiates the transcription of the corresponding 
target gene (Carson-Jurica et al., 1990). This process is illustrated in Figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic overview of steroidogenic targeting.  
Steroids target specific nuclear receptors, therefore each individual steroids has a unique spectrum of 
activity. Steroid hormones are divided into at least five classes (Table 1), which include the major 
active and inactive forms (Miller, 1988).  
Table 1: Overview of steroid classification 
  
 Scaffold 
(number of 
carbons) 
Major inactive steroid Major active steroid(s) 
Glucocorticoids 21 
Cortisone (human) 
11-Dehydrocorticosterone (rodent) 
Cortisol (human) 
Corticosterone (rodent) 
Mineralocorticoids 21 no inactive precursor steroid 
11-Deoxycorticosterone 
and 
Aldosterone 
Androgens 19 Androstenedione 
Testosterone/ 
Dihydrotestosterone 
Estrogens 18 Estrone Estradiol 
Progestogens or 
Progestins 
21 Pregnenolone Progesterone 
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2.2 Steroidogenesis 
Steroidogenesis, the understanding and unveiling of the mechanism of biosynthesis of steroid 
hormones, is a highly competitive field within biochemical research. Major research efforts have 
focused on the cloning of steroidogenic enzymes, identifying their multiple isoforms, characterizing 
known and novel pathways responsible for the formation of active steroids and investigating tissue 
specific expression of steroidogenic enzymes in health and disease (Payne and Hales, 2004). 
Figure 3 shows a schematic overview of the most abundant steroid hormones in humans and the 
enzymes responsible for their formation (Luu-The, 2013; Payne and Hales, 2004).  
 
 
 
 
 
 
 
 
 
Figure 3: Schematic overview of the steroidogenesis. The main active steroids are in bold, 
cytochromes are in blue, HSDs in green, and the 5α-steroid reductase is in red.  
The cytochrome P450 (CYP) enzymes involved in steroidogenesis are membrane bound proteins 
associated with either the mitochondrial membrane (CYP11A, CYP11B1, CYP11B2) or the 
microsomal endoplasmic reticulum (CYP17, CYP19, CYP21) (Nelson et al., 1996). Hydroxysteroid 
dehydrogenases consist of a multitude of enzymatic superfamilies, three of which; aldo-
ketoreductases (AKR) (17βHSD5), short chain dehydrogenases/ reductases (3β-HSDs and 17β-
HSDs) and steroid 5α-reductases (5α-reductase 1 and 2) play an important role in steroidogenesis 
(Jornvall et al., 1995; Krozowski, 1994; Stiles and Russell, 2010). 
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2.3 Steroid hormones in health and disease 
The binding of steroids to their cognate nuclear receptor impacts on many physiological pathways 
including development, metabolism, immune system, psychology and behavior both for example, in 
health and disease (Knoedler and Denver, 2014). Isoforms of the glucocorticoid receptor (GR) are 
expressed ubiquitously in all types of tissues. Since glucocorticoids play important anti-inflammatory, 
anti-proliferative, pro-apoptotic and anti-angiogenic roles, synthetic derivatives of them are very 
effective in treating various diseases and have been a focus of pharmaceutical research for decades. 
Androgens play a key role in male sexual and reproductive development and health (MacLusky et al., 
1997; Marcell et al., 2011). Additionally, androgens are key determinants in the prevention and 
development of cardiovascular disease (Mercuro et al., 2010; Vitale et al., 2009). The role of 
androgens and progestins in the development and progression of a variety of cancers are widely 
acknowledged, and are the focus of many research groups worldwide. The major role of aldosterone is 
the regulation of sodium and potassium homeostasis. Therefore, aldosterone is a key regulator of 
blood pressure and is implicated in many diseases involving the kidney such as aldosterone-
dependent kidney damage (Zennaro et al., 2013) (Wu et al., 2009). A dysregulation of aldosterone 
levels results in blood pressure-independent pathologies such as myocardial fibrosis (Freel et al., 
2012) and diabetes mellitus (Reincke et al., 2010). The pathological effects of steroid hormones arise 
due to a misbalance in the levels of active/ inactive hormones and /or an impaired receptor sensitivity 
and disturbed signaling. Furthermore, the mineralocorticoid receptor (MR) plays a role in the regulation 
of immune functions and an excessive activity has been associated with oxidative stress and 
inflammation (Odermatt and Kratschmar, 2012). To conclude, the enzymes activating and deactivating 
the steroid hormones play key roles in every aspect of development, health and disease. 
2.4 Hydroxysteroid dehydrogenases are key pre-receptor control 
elements regulating the balance between active and inactive 
hormones 
Hydroxysteroid dehydrogenases (HSDs) are enzymes which catalyze positional and stereospecific 
reactions on ketone or hydroxyl groups on the steroid hormone (Penning, 2011). In steroid hormone 
target tissues, HSDs co-exist in pairs which interconvert potent active steroids to the cognate inactive 
metabolite and vice versa. Therefore, HSDs act as an intracellular switch which regulates the amount 
of ligand available for the nuclear receptor (Labrie et al., 2000; Penning, 2003). This selective control 
is maintained by the HSDs which function preferentially as either nicotinamid adenine dinucleotide 
phosphate hydrogen (NADPH)-dependent ketosteroid reductases or as NAD+-dependent 
hydroxysteroid oxidases (Penning, 2011). The HSDs responsible for the interconversions belong to 
two large gene superfamilies; the aldo-keto reductases (AKRs) and the short chain dehydrogenase 
reductases (SDRs) (Bauman et al., 2004) (Jornvall et al., 1995). Figures 4a and 4b show the two 
superfamilies and how they function to control the cellular levels of nuclear receptor ligand availability.  
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Figure 4a: Overview of the AKR superfamily (Penning, 2011) 
(used with permission from Elsevier) 
 
 
 
 
 
 
 
 
 
 
Figure 4b: Overview of the SDR superfamily (Penning, 2011) 
(used with permission from Elsevier) 
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2.5 11β-Hydroxysteroid dehydrogenase type 1 and type 2  
The interconversion of cortisone and cortisol in humans and of 11-dehydrocorticosterone and 
corticosterone and in rodents is catalyzed by the enzymes 11β-hydroxysteroid dehydrogenase (11β-
HSD) type 1 and type 2, respectively (Funder et al., 1988). The catalysis of the inactive steroid 
cortisone to the potent GR and MR agonist cortisol by 11β-HSD1 was first reported in 1953 (Amelung 
et al., 1953). Initially, it was considered that the oxidation of cortisol and the reduction of cortisone 
were catalyzed by a single microsomal enzyme. More than 30 years later, in 1985, evidence confirmed 
the enzymatic oxidase and the reductase activity, were by two independent processes and therefore 
two enzymes were described (Lakshmi and Monder, 1985). 11β-HSD1 catalyzed the reduction of 
cortisone and 11β-HSD2 catalyzed the oxidation of cortisol. In vivo, 11β-HSD2 is most probably a 
strictly unidirectional enzyme. However, Rebuffat et al. could show that 11β-HSD2 is a reversible 
enzyme and is able to reduce 11-ketodexamethasone, a synthetic glucocorticoid to dexamethasone in 
HEK-293 cells transiently expressing 11β-HSD2 (Rebuffat et al., 2004). In vivo, 11β-HSD1 acts 
predominantly as a reductase, however, in states of NADPH deficiency, it can exhibit dehydrogenase 
activity (Lavery et al., 2006). Figure 5 shows the interconversion of cortisone and cortisol catalyzed by 
11β-HSD1 and 11β-HSD2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Interconversion of cortisone and cortisol catalyzed by 11β-HSD1 and 11β-HSD2,  
2.5.1 Properties and expression of 11β-hydroxysteroid dehydrogenases 
The two kinetically distinct forms of 11β-HSD (11β-HSD1 and 11β-HSD2) are differentiated by their 
metabolic directionality, cofactor specificity and tissue distribution. Cortisone shows no biological 
activity, explained by negligible affinity for GR and MR (Agarwal et al., 1989; Tannin et al., 1991; 
Walker et al., 1992). 11β-HSD1 expression and activity is present in most tissues, but is most 
abundant in the liver. The Km of 11β-HSD1 for cortisone is within the micromolar range, which is much 
higher than that of 11β-HSD2 for cortisol, which is in the nanomolar range. 11β-HSD1 oxidizes the 
reduced form of NADPH. 11β-HSD1 knockout mice show elevated levels of corticosterone 
(corticosterone in rodents is the equivalent to cortisone in human). These mice show reduced 
glucocorticoid responses, including a strong down regulation of gluconeogenesis following fasting. The 
Introduction 
18 
lipid profiles in the 11β-HSD1 knockout mice were improved, and there was no effect on blood 
pressure reported (Holmes et al., 2001; Kotelevtsev et al., 1997; Morton et al., 2001). In contrast, the 
expression of 11β-HSD2 is limited. Immunohistochemical studies show that 11β-HSD2 is localized in a 
distinct set of organs and tissues which are primarily involved in the transepithelial transport of sodium 
such as the distal renal tubules (mainly cortical collecting duct), distal colon, sweat and salivary 
glands. In addition, 11β-HSD2 is also expressed in the vascular wall and in the placenta (Albiston et 
al., 1994; Benediktsson et al., 1993; Krozowski et al., 1995; Naray-Fejes-Toth et al., 1991). 
2.5.2 11β-Hydroxysteroid dehydrogenase type 2 is co-expressed with the 
mineralocorticoid receptor in epithelial cells 
In 1983, Krozowski and Funder showed that the in vitro affinities of the MR towards aldosterone and 
cortisol were identical (Krozowski and Funder, 1983). However, in contrast, the MR in specific tissues 
is selective for aldosterone. Edwards et al. later showed that the organs with aldosterone selectivity 
such as the kidney have much higher levels of 11β-HSD2 than MR expressing tissue with no 
aldosterone selectivity (Edwards et al., 1988). It soon became clear that there are two distinct types of 
MR expressing tissues: Firstly, tissues co expressing 11β-HSD2 and MR; the role of 11β-HSD2 in 
these tissues is to serve as a “gate-keeper” to maintain aldosterone selectivity and to protect the MR 
from high glucocorticoid concentrations (Edwards et al., 1988; Funder et al., 1988); secondly, tissues 
in certain brain regions (hippocampus), immune cells (microglia, macrophages) and others, where the 
MR function is mainly regulated by glucocorticoids (Roland et al., 1995) (Odermatt and Kratschmar, 
2012). 
2.5.3 11β-Hydroxysteroid dehydrogenases 1 interacts with hexose-6 phosphate 
dehydrogenase 
A further level of tissue-specific glucocorticoid regulation was revealed following the discovery that 
hexose-6 phosphate dehydrogenase (H6PDH) plays an important role in the determination of the 
reaction direction of 11β-HSD1 (Atanasov et al., 2004; Banhegyi et al., 2004). It was shown that in 
tissues where 11β-HSD1 is co-expressed with H6PDH, such as the liver, adipose tissue or skeletal 
muscles (Gomez-Sanchez et al., 2008), 11β-HSD1 functions as a reductase. H6PDH is a key enzyme 
in the pentose phosphate pathway in the endoplasmic reticulum and catalyzes the reaction of glucose-
6-phosphate to 6-phosphogluconolactone to generate NADPH (Mason et al., 1999; Ozols, 1993).  
Dzyakanshik et al showed in microsomal preparations of HEK-293 cells expressing 11β-HSD1 that a 
NADPH/NADP+ ratio of ten or higher was required for efficient 11β-HSD1 reductase activity 
(Dzyakanchuk et al., 2009). Such observations suggest that an intraluminal change in the 
NADPH/NADP+ redox coupling causes a shift in the activity of 11β-HSD1 from reductase to 
dehydrogenase. 
2.5.4 11β-Hydroxysteroid dehydrogenases in health and disease 
Glucocorticoids are involved in almost every aspect of development, physiologically and 
psychologically, and in health as well an in disease. Cortisol is involved in lipid synthesis and it plays 
an important role in carbohydrate metabolism and protein turnover. Glucocorticoids are key regulators 
of stress responses, neuronal functions, cell growth and differentiation, blood pressure and immune 
functions (Sapolsky et al., 2000). The importance of a functioning glucocorticoid regulatory system is 
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demonstrated in the GR knock-out mice, which die within hours after birth (Cole et al., 1995). Beyond 
the primary function of 11β-HSD1 as a key switch to provide active glucocorticoid hormones and 
modulate local glucocorticoid dependent gene expression, 11β-HSD1 acts as key enzyme in the 
regulation of metabolic functions. Elevated 11β-HSD1 activity has been associated with metabolic 
disorders. Obesity studies in genetically obese rodents (Zucker rats and Leptin-deficient (ob/ob) mice) 
have shown that 11β-HSD1 mRNA and enzyme activity are significantly increased in adipose tissue. 
(Livingstone et al., 2000; Masuzaki et al., 2001). These findings could be confirmed in obese humans 
(Rask et al., 2002). It has also been shown, in contrast, the levels of hepatic 11β-HSD1 mRNA and 
activity are reduced (Rask et al., 2002; Stewart et al., 1999). Transgenic mice with adipose specific 
11β-HSD1 overexpression were generated to study the adverse effects of 11β-HSD1 up regulation 
(Masuzaki et al., 2001). These mice showed a marked insulin resistance, glucose intolerance, 
elevated levels of free fatty acids and triglycerides, apparent leptin resistance and angiotensin 
overexpression driven hypertension (Masuzaki et al., 2001; Masuzaki et al., 2003). All these findings 
support the research carried out in 11β-HSD1 knock-out mice. 11β-HSD1-deficient mice are resistant 
against hypoglycemia which normally appears upon stress or high fat diet (Kotelevtsev et al., 1997). 
Generally, 11β-HSD1-deficient mice show a cardioprotective phenotype, with reduced serum 
triglycerides and raised high density lipoprotein cholesterol (Morton et al., 2001). Rare human 
cortisone reductase deficiency is presented by excessive adrenal androgen production as a 
consequence of enhanced metabolic clearance of cortisol and compensatory HPA axis activation 
(Phillipov et al., 1996). Drugs selectively targeting 11β-HSD1 for cardioprotective effects are currently 
being investigated (Barf et al., 2002). However, the role of 11β-HSD1 seems to be diverse and is yet 
not fully understood. Accordingly, 11β-HSD1 inhibition might bear risks and lead to unwanted effects.  
Deficiency of renal 11β-HSD2 allows glucocorticoids to constantly activate the MR in the distal tubule. 
This deficiency, which is named syndrome of apparent mineralocorticoid excess (SAME) (Ulick et al., 
1979) results in sodium retention, severe hypertension and hypokalemia (Edwards et al., 1988; 
Stewart et al., 1988; Stewart et al., 1987). To have a model for studying this severe hypertensive 
condition, Kotselev et al. produced 11β-HSD2 knockout mice. (Kotelevtsev et al., 1999) Fifty percent 
of the homozygous mice died within two days following birth, often due to sudden cardiac arrest. 
Surviving adult animals suffered multiple conditions caused by severe hyperkalemia (Kotelevtsev et 
al., 1999), the most distinct phenotype being hypotonic polyuria (Berl et al., 1977). Blood pressure was 
elevated markedly in both, male and female 11β-HSD2-deficient mice.  
Besides the roles discussed above, within the regulation of the metabolism, homeostatic processes 
and energy supply, 11β-HSD1 is an important enzymes in the central nervous system. Glucocorticoids 
affect neurotransmitters, receptors, channels and metabolism in the brain (De Kloet et al., 1991). 
Some regions of the brain such as the hippocampus, are especially sensitive to glucocorticoids 
(McEwen, 1999). 11β-HSD1 is highly expressed in these areas, whereas 11β-HSD2 is almost absent 
(Robson et al., 1998). Aging 11β-HSD1-deficient  mice have better learning abilities compared with 
aged-matched wild type mice (Penning, 2011). It is hypothesized, that the reduced interhippocampal 
corticosterone levels in the knock-out mice may be the reason for the improved learning abilities 
(Penning, 2011).  
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2.6 Focus on the short chain dehydrogenase/reductase family 
member 17β-hydroxysteroid dehydrogenase type 3 
2.6.1  Properties and expression of 17β-hydroxysteroid dehydrogenase type 3 
In 1994, Geissler et al reported the isolation of the cDNA and the gene encoding for the short-chain 
dehydrogenase/reductase 17β-Hydroxysteroid dehydrogenase type 3 (17β-HSD3) (Ulick et al., 1979). 
They were the first to show that 17β-HSD3 is a testicular enzyme which catalyzes the reduction of the 
weak androgen ∆4-androstene-3, 17-dione to the potent androgen testosterone utilizing NADPH as 
cofactor. Testosterone can be further converted to dihydrotestosterone (DHT) by members of the 5α- 
reductase family (Stewart et al., 1988) (Figure 6).  
 
 
 
 
 
Figure 6: Conversion of androstenedione into testosterone and dihydrotestosterone.  
The target receptor of testosterone, the androgen receptor (AR), is unique among the hormone 
receptors because it has two biologically high affinity binding hormones that are different in their 
physiological potency (Stewart et al., 1987). Testosterone, the product of 17β-HSD3 and 17β-HSD5 
(organ specific expression) is the major androgen in muscle and shows anabolic properties starting in 
puberty. DHT also has its own distinct tasks during male development. Human male fetal genital 
development is impaired in individuals with normal testosterone levels but no DHT expression, the 
result of a genetic defect in 5α-reductase (Bormann et al., 2011). 
Often conversion from androstenedione to testosterone is determined as a direct measure for 17β-
HSD3 expression. This method is flawed, since is does not distinguish between the conversion of 
androstenedione to testosterone by 17β-HSD3 and 17β-HSD5. A decade ago, it was believed that 
17β-HSD3 is exclusively expressed in the Leydig cells of the testis (Geissler et al., 1994; Payne and 
Hales, 2004). More recent reviews provide evidence that 17β-HSD3 is predominately, but not 
exclusively expressed in the testis (George et al., 2010). An interesting study carried out by Corbould 
et al. investigated whether 17β-HSD3 is co expressed with CYP19 (aromatase) in preadipocytes in 
women and whether the expression pattern of these two enzymes is different in subcutaneous versus 
intra-abdominal adipose tissue (Corbould et al., 2002). They observed the presence of 17β-HSD3 
mRNA in preadipocytes but not in mature adipocytes.  
Interestingly, generalized obesity (Body mass index (BMI) as measure) or central obesity (judged by 
waist circumference) was correlated with the ratio of 17β-HSD3 mRNA: aromatase mRNA. This effect 
differed in adipose tissue derived from abdominal and intra-abdominal sites. A study carried out in 
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women showed an expression pattern suggesting that obesity is associated with a decline in 17β-
HSD3 mediated testosterone production in subcutaneous abdominal adipose tissue and an increase 
in 17β-HSD3 mediated testosterone production in the intra-abdominal adipose tissue (Corbould et al., 
2002). 17β-HSD3 is also expressed in the brain, in sebaceous glands and in bones (George et al., 
2010). 
2.6.2 17β-Hydroxysteroid dehydrogenase type 3 deficiency  
Testosterone is produced in the Leydig cells of the male embryo as early as eight weeks of gestation 
(Jost, 1970). It is primarily used to stabilize the Wolffian duct (Tong et al., 1996), an embryonic 
structure forming the epididymis, vas deferens and the seminal vesicles. Later, testosterone and DHT 
induce the formation of the male genitalia (penis, prostate, urethra and scrotum) (Wilson, 1978). 
17β-HSD3, 5α-reductase and AR are key elements in the production and the signaling of testosterone 
and DHT and dysregulation in any of these factors, including 17β-HSD3, can result in the 46 XY 
disorder of sex development (DSD) (George et al., 2010). The definition of DSD is quite broad and 
includes any congenital condition in which the development of chromosomal, gonadal or anatomical 
sex is atypical (Houk et al., 2006; Hughes et al., 2006). DSDs are characterized into three distinct 
categories; sex chromosome DSD, 46 XX DSD and 46 XY DSD. The designation 46 XY DSD was 
proposed to replace the former term of male pseudohermaproditsm, according to the consensus 
statement (Houk et al., 2006; Hughes et al., 2006). Commonly, patients with the 46 XY DSD suffer 
from androgen insensitivity syndrome. However, a small number of 46 XY DSD patients have 
deficiencies in 17β-HSD3 or 5α-reductase (George et al., 2010). A deficiency of 17β-HSD3 leads to an 
autosomal recessive form of 46 XY DSD which was first described in 1971 by Saez et al.(Saez et al., 
1971; Saez et al., 1972). Mutations in the HSD17B3 gene can lead to a broad spectrum of 46 XY 
DSD, ranging from completely undervirilized external female genitalia, ambiguous to predominantly 
male genitalia with a micropenis and hypospadias (birth defect of urethra) (Boehmer et al., 1999). 
Twenty seven different mutations in the HSD17B3 gene have been identified and characterized (Mains 
et al., 2008). 17β-HSD3 mutations range from missense mutations, exonic deletions and mutations 
within the intrinsic splice site (George et al., 2010). 1 in 5000 people worldwide carry DSD mutations, a 
figure surprisingly high (Sax, 2002; Thyen et al., 2006). 17β-HSD3 deficiency is present in about 1 in 
147’000 newborns in Europe (Boehmer et al., 1999). Among the Gaza Strip Arab population, the 
prevalence is reported to be as high as 1 in 100-300 newborns because of the high consanguinity 
(Rosler, 2006; Rosler et al., 1996). 
Only about 50% of the children suffering from 46 XY DSD get a definitive diagnosis, therefore, it is 
difficult to determine the true prevalence (Hughes et al., 2006). The clinical presence at birth is often 
atypical, since female external genitalia are present (Rosler, 2006). Therefore, the phenotype of the 
mutation often remains unnoticed at birth. The newborns are usually registered as females and it is not 
until adolescence that they are correctly diagnosed (Rosler, 2006; Twesten et al., 2000). At the time of 
puberty, DSD patients show varying degrees of virilisation, including development of a male body 
habitus, increased body hair and a deepening of their voice (Lee et al., 2007). The impaired late onset 
development of the penis may be due to peripheral conversion of testosterone (Balducci et al., 1985). 
The female to male gender change is relatively frequent in 46 XY DSD sufferers, at approximately 39- 
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64 % (Hiort et al., 2003). If the 17β-HSD3 deficiency is discovered early, patients commonly undergo 
gonadoectomy in childhood (prepubertally) in order to and maintain the female phenotype and gender 
role (Bertelloni et al., 2009).  
2.7 Focus on the aldo-keto reductase family member 17β-
hydroxysteroid dehydrogenase type 5 (AKR1C3) 
In vitro, 17β-HSD5 catalyzes the interconversion of the alcohol group to the carbonyl group and vice 
versa at position 17 on the steroid backbone. Due to the high ratio of the cofactor NADPH to NAD+ 
17β-HSD5 mainly acts as a reductase in vivo (Penning et al., 2000). Lin et al. cloned 17β-HSD5 from 
a human prostate cDNA library and proposed that the recombinant enzyme reduced the potent 
androgen 5α-DHT to the weaker androgen 3α-androstanediol (Lin et al., 1997). The reverse reaction 
could not be shown. Later, Dufort, Luu-The and others showed that 17β-HSD5 catalyzes the same 
reaction as 17β-HSD3; the reduction from the weak androgen androstenedione to the potent androgen 
testosterone (Dufort et al., 1999; Labrie et al., 1997c). Furthermore, they showed that the activity of 
17β-HSD5 is destroyed upon homogenization of cells or tissue samples and therefore suggested that 
the 17β-HSD5 enzymatic reaction proposed by Lin et al. was incorrect. Dufort et al. hypothesized that 
the reaction observed by Lin et al was instead catalyzed by 3α-HSD. This hypothesis was later 
confirmed (Luu-The et al., 2001; Qin et al., 2006) and it is now generally accepted that 17β-HSD5, in 
addition and equally to 17β-HSD3, catalyzes the reaction from androstenedione to testosterone. 
However, 17β-HSD5 and 17β-HSD3 differ in their tissue distribution. 17β-HSD3 is mainly expressed in 
the testis, whilst 17β-HSD5 is mainly present in the prostate and the mammary glands (Penning et al., 
2000). Other tissues where 17β-HSD5 is expressed include lung, liver, uterus, small intestine, brain 
and to a very low extent in testis (Penning et al., 2000).  
2.7.1 The role of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) in prostate cancer 
Prostate cancer is amongst the most frequently diagnosed cancers worldwide and one of the leading 
causes of cancer-related deaths in men worldwide (Jemal et al., 2011). Although there are still many 
questions to be answered in respect to the initiation and progression of prostate cancer, two major 
mechanisms, which both result in the activation of the androgen axis have been studied extensively 
(Knudsen and Penning, 2010). The first mechanism involves the over-activation of AR by 
amplification, overexpression or mutations of the AR (Lapouge et al., 2008; Reddy et al., 2006). The 
second mechanism is focuses on AR ligands and involves either their de novo synthesis or the 
increased enzymatic conversions to active androgens (Hofland et al., 2010; Pfeiffer et al., 2011). Since 
17β-HSD5 is highly expressed in the prostate, it plays an important role in the synthesis of 
testosterone which is a strong stimulus for growth, activation, proliferation and metastasis of prostate 
cancer cells. Furthermore, upon inhibition of the 5α-reductase by finasteride, a cornerstone drug to 
treat prostate cancer, it was shown in vitro in the prostate cancer cell line LnCap that 17β-HSD5 was 
up regulated (Pfeiffer et al., 2011). This cellular adaption process in response to testosterone and DHT 
deprivation can result in a resistance to the 5α-reductase inhibitor finasteride (Byrns et al., 2012). 
Increased angiogenesis markers and proliferation in the prostate cancer cell line PC-3 was shown by 
Dozmorov et al.(Dozmorov et al., 2010). Several studies have reported a strong up regulation of 17β-
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HSD5 in different types of prostate cancers (Fung et al., 2006; Nakamura et al., 2005). In conclusion, 
the evidence shows that there is a correlation between the expression levels of 17β-HSD5 and the 
progression of prostate cancer, however, the distinct mechanism of action linking these observed 
correlations remain unclear and will be in the focus of many researchers in the future.  
2.8 The pleiotropic effects of testosterone 
Testosterone, the product of the reduction of androstenedione catalyzed by the enzymes 17β-HSD3 
and 17β-HSD5, exerts a vast amount of biological actions and plays key roles in many physiological 
and pathological processes throughout life, starting in the early embryonic phase. Testosterone levels 
in plasma or serum vary over three orders of magnitude depending on age, gender and health 
(Rosner et al., 2007). Testosterone levels also follow a circadian rhythm, therefore, fixed standard 
levels do no not exist (Rosner et al., 2007). Only 1-3 % of the circulating testosterone is free, the rest 
is plasma protein bound and there is no convention whether the free or the bound testosterone is the 
more useful measure (Rosner et al., 2007). Mean total testosterone levels in healthy, middle aged 
men are between 300 and 600 ng/dl (10.4-20.8 nM/ L). Corresponding female levels are between 20 
and 40 ng/dl (0.7-1.4 nM/L). 
2.8.1  Male embryonic development is testosterone dependent 
Normal gonad and genitalia development takes place in three sequential stages; the undifferentiated 
stage where XX and XY embryos show the same structures, the gonadal determination phase and 
finally the phase where internal and external genitalia are differentiated (McLachlan et al., 2002). In 
the presence of testicular hormones (mainly testosterone and DHT) the differential phase is driven 
towards the male development pathway. Jost’s (Jost, 1970) conclusions from very early experiments 
have been confirmed by recent observations: The adequate production and action of testosterone is 
the key factor for the development and differentiation of the internal and external genitalia in males 
(Walker, 2009).  
2.8.2 Male fertility and sexual health is driven by testosterone  
Male fertility is primarily dependent on spermatogenesis. Testosterone is essential for the production 
of spermatozoa (McLachlan et al., 2002). Most testosterone is produced locally by Leydig cells. 
Testosterone levels in adult testis is remarkably stable (Walker, 2009). Besides its key role in fertility 
testosterone is also responsible for many different aspects of sexual function, such as sexual desire 
and erectile functions (Finkelstein et al., 2013). 
2.8.3 The role of testosterone in metabolism 
Testosterone, besides its most obvious and known roles in fertility and sexuality, is an important 
regulator of carbohydrate, fat and protein metabolism (Kelly and Jones, 2013). The metabolic 
syndrome, which is defined as a cluster of risk factors for cardiovascular diseases and diabetes 
mellitus type 2 (DMT2), is an emerging problem worldwide (Alberti et al., 2009). Following a joint 
statement of international diabetes and heart associations, to be diagnosed with the metabolic 
syndrome, patients must exhibit a minimum of three of the following criteria (Alberti et al., 2009):  
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 Elevated waist circumference (ethnic-specific) 
 Elevated triglycerides (≥ 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides  
 Reduced high density lipoprotein (HDL) (in males ≤ 50 mg/dL (1.3 mmol/L), in females ≤ 40 
mg/dL (1.0 mmol/L)) or drug treatment for reduced HDL 
 Elevated blood pressure (systolic ≥ 130 and/or diastolic ≥ 85 mm Hg) or antihypertensive drug 
treatment in a patient with a history of hypertension 
 Elevated fasting glucose (≥ 100 mg/dL) or treatment for elevated glucose 
 
The metabolic syndrome is a condition recognized by the World Health Organization (WHO) to be 
associated with an increased risk of myocardial infarction, stroke and cardiovascular death. The 
central biochemical defect associated with the metabolic syndrome and DMT2 is a reduced sensitivity 
to insulin, known as insulin resistance (Alberti et al., 2009). 
 
Epidemiological studies show, that up to 40% of men with DMT2 have testosterone deficiency and that 
endogenous, both total and free testosterone was lower in men with metabolic syndrome compared to 
healthy men (Corona et al., 2011). Despite the focused research on this topic, the relationship 
between testosterone and metabolic syndrome is not yet fully understood. It seems that there is a 
bidirectional effect of this disease, where obesity induces androgen deficiency and hypogonadism 
(associated with low androgen levels) contributes to obesity (Cohen, 1999; Laaksonen et al., 2005).  
Cardiovascular disease (CVD) linked with the metabolic syndrome is a major cause of morbidity and 
mortality in older men (Shores et al., 2014). CVD in elder man may be related to decreased 
testosterone levels, which are associated with the metabolic syndrome (Haring et al., 2011; Muller et 
al., 2005; Svartberg et al., 2006). Although the evidence suggests, that low levels of testosterone are 
associated with risk factors, it was not known whether low testosterone is independently associated 
with a higher risk for CVDs. To investigate this question, Shores et al. recently published a longitudinal 
cohort study to evaluate whether total testosterone, unbound (free) testosterone, DHT and unbound 
(free) DHT were associated with incident CVD and mortality in men who were free of CVD at the time 
of blood collection (Shores et al., 2014). The study showed that total and free testosterone were not 
associated with CVD events while the levels total and free DHT showed curvilinear associations (high 
risk at low levels, lower risk at medium levels, high risk at high levels).  
2.8.4 Testosterone and prostate cancer - a paradigm shift 
It has been more than 40 years since the relationship between serum testosterone levels and prostate 
cancer progression was first described by Hodges and Huggins (Huggins and Hodges, 1972). 
Androgen deprivation therapy is today the cornerstone of treatment for men with advanced prostate 
cancer. Testosterone replacement therapy in elder man is therefore contraindicated if prostate cancer 
is diagnosed (Apostolova et al., 2005; Legeza et al., 2013).  
 
However, in multiple longitudinal studies, an association between prostate cancer and endogenous 
testosterone levels has never been found (Dohle et al., 2003). Multiple studies in animal systems show 
a dose response curve for prostate growth with respect to androgen concentrations (Dohle et al., 
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2003). However, at higher concentrations, a plateau in prostate tissue growth is reached and any 
further increase in androgen concentration produces little or no further growth (Dohle et al., 2003). 
Overall, there is no evidence to support the long standing assumption that high circulating 
testosterone levels directly contribute to the development of  prostate carcinoma (Giovanni Luca et al., 
2013). However, prostate cancer tumors are extremely sensitive to variations in testosterone 
concentrations in the serum. There is evidence, that prostate cancer behaves in an androgen 
dependent manner at low testosterone concentrations and becomes androgen indifferent at higher 
concentrations. Saturation models describing the relationships of prostate tumor growth and 
testosterone concentrations proposed by Morgentaler and Traish (Helsen et al., 2014) are primarily 
based on the finite capacity of the AR to bind androgens (Wilson, 1975; Wilson and Walker, 1969).  
2.8.5 The role of testosterone in male breast cancer is not yet understood 
The role of testosterone in male breast cancer development in not yet fully understood (Samson et al., 
2010). Several studies and case reports indicate a relationship between breast cancer and 
testosterone levels (M. Samson, 2010; Samson et al., 2010). It is hereby important to mention, that 
especially the amount of testosterone produced locally (intracrine) within the breast cancer tissue is 
critical for the growth of the tumor (Jobling et al., 2002; Labrie et al., 2000). Furthermore, it was 
suggested that high testosterone levels may lead to an increase in aromatization and therefore to 
higher estradiol levels. Estradiol may stimulate the estrogen receptor (ER) in the breast tissue and 
increase the risk of male breast cancer (Andersson and Russell, 1990). These aspects are also 
relevant regarding triple-negative, AR positive breast cancer in women. 
2.8.6 Testosterone and cognition 
In respect to the increasing life expectancy worldwide, age-related dementia is a growing problem. 
Age related cognitive decline and dementia is not fully understood. Serum testosterone decreases with 
age in men (Auchus, 2004). From the age of 30 years, on average per year, total testosterone 
decreases by 0.2- 1% and free testosterone by 2-3% (Kamrath et al., 2012). There is evidence that 
sex hormones such as testosterone or estradiol can exhibit protective functions in the brain, especially 
in regions which are known to have a high density of AR (Attard et al., 2012; Mahendroo et al., 2004). 
Through its binding to AR, testosterone or its downstream metabolite estrogen act as neuroprotectors 
by modulating neuronal damage caused by oxidative stress (Rahman and Huhtaniemi, 2004) as well 
as reducing neuronal apoptosis (Saez, 1994). Oxidative stress and apoptosis both play important roles 
in dementia. Clinical trials performed by Cherrier et al., examining the effects of testosterone 
supplementation on memory function in an eugonadal man showed a significantly improved memory 
and visuo-spatial function compared to the placebo groups (Baek et al., 2006; Nagpal et al., 1994). In 
other studies, curvilinear associations between free testosterone levels and working memory 
(McEwan, 2013), verbal memory (Mangelsdorf et al., 1995) and attention (Khorasanizadeh and 
Rastinejad, 2001) have been found, suggesting the beneficial effects of testosterone at the 
appropriate doses. Overall, there is growing evidence to support the hypothesis that testosterone 
exerts neuroprotective effects and exhibits positive effects on cognition and memory. However, the 
results are not conclusive since it appears that serum levels of testosterone in relation to its beneficial 
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effects are curvilinear, with the beneficial effects of testosterone shown at medium serum 
concentrations, whereas there are no beneficial effects at low and high levels of testosterone.  
2.8.7 The Janus face of testosterone when it comes to muscles, bones and strengths - 
clinic and doping  
Testosterone is a member of the anabolic androgenic steroids (AAS) which are known to promote 
muscle building. In myocytes, testosterone or its synthetic derivatives bind to the AR initiating a 
cascade of anabolic processes. At a supraphysiological dose of 300 mg testosterone enanthate per 
week, muscle strength and endurance are markedly increased in healthy young men after only three 
weeks compared with placebo (Yamana, 2010). Testosterone therapy is used in the clinic to aid 
muscle building and development in primary and secondary hypogonadism. It has been shown that in 
men with pulmonary diseases (Shores et al., 2014) or in elderly men in rehabilitation (Muller et al., 
2012) that muscle strength or physical function improved after testosterone replacement therapy. In 
concordance with this finding, two placebo controlled trials in frail, elderly men and in men with limited 
mobility showed beneficial effects both on leg- and chest-press as an indication of muscle strength, 
upon  testosterone administration compared to the placebo group (Davis et al., 2011; Rosenfield and 
Otto, 1972). In contrast, no improvement in muscle strength could be observed in two placebo 
controlled studies in healthy elderly men (Davis et al., 2011; Zouboulis et al., 2007). Focusing on 
strength and fitness, testosterone also plays an important role in the maintenance of bone density in 
man. Low androgen levels caused by hypogonadism or androgen deprivation therapy is clearly related 
to a higher incidence of osteoporosis and rapid bone loss (Stepan et al., 1989). Studies have shown 
bone structural parameters such as the microarchitecture and bone mineral density are impaired in 
men with hypogonadism (Benito et al., 2003). In men with low testosterone levels at the start of the 
study, significant increased lumbar spine bone density was observed (Zouboulis et al., 2007). 
However, another clinical trial in men with testosterone levels in the low-normal range showed that 
testosterone replacement therapy did not change bone density (Davis et al., 2011). It appears that the 
muscle strength, endurance and bone density can only be positively influenced by testosterone 
replacement therapy if the endogenous testosterone level is lower than the normal, age dependent 
value.  
 
Despite the known and lethal side effects, testosterone and its derivatives are very popular doping 
agents. They are historically the “first” doping agents introduced in the 1950s to enhance performance 
among weightlifters (Duntas and Popovic, 2013). In later chapters of this thesis, I will introduce ASS in 
more detail. 
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3. Project 1:  
Evaluation of anabolic androgenic steroids regarding their 
effect on 11β-hydroxysteroid dehydrogenase 2-dependent 
glucocorticoid inactivation  
3.1 Introduction anabolic androgenic steroids 
Anabolic androgenic steroids (AAS) are synthetic steroids, derivatives of the male sex hormone 
testosterone (androgen), which promote the development of male sexual characteristics (androgenic 
effect) and growth of skeletal muscle (anabolic effect). Since the fifties when AAS were first introduced 
and used predominately by weight-lifting top athletes, there has been a huge drive to modify and 
improving these substances. Today, more than 1000 testosterone derivatives are known. Since 
testosterone undergoes a rapid hepatic metabolism when administered orally, a lot of  new 
compounds that show improved bioavailability and metabolic stability were designed (van Amsterdam 
et al., 2010).  
According to their metabolic and chemical properties, AAS are classified into three groups (Hall, 
2005):  
a) Class A: 17β-hydroxylated testosterone esters. These steroids show improved lipid solubility. 
Intramuscular dosing is required.  
b) Class B: Testosterone derivatives which are alkylated at the 17α-hydroxyl position. These 
compounds can be administered orally. 
c) Class C: Derivatives alkylated at ring A, B or C (Figure 1) of the steroid backbone. These 
steroids are orally available and resist hepatic metabolism.  
3.1.1 The different types of ASS users - prevalence data 
Whereas ASS were initially solely used by elite athletes and bodybuilders, ASS abuse spread into 
different population groups within the last three decades (Kanayama et al., 2008). Surprisingly, it is 
even estimated, that elite athletes form the smallest group of ASS abusers (Bahrke and Yesalis, 
2004). The highest ASS abuse prevalence occurs within people participating in recreational sport 
(Bahrke et al., 2000). Men abuse ASS about three times more than women (Bahrke et al., 2000). 
Another subgroup of ASS users is formed by individuals who consume ASS either for occupational or 
for aesthetic purposes (Bahrke and Yesalis, 2004; Monaghan, 2002). A study from 2007 (Cohen et al., 
2007) shows another, completely different profile of a typical ASS user: Cohen et al. recruited 1955 
males via sport- and muscle-building related webpages. The internet was chosen on purpose, to 
guarantee the most possible anonymity expecting to obtain honest answers. According to this study, 
the typical ASS user holds a university degree (minimum Bachelor’s degree), earns an above-average 
income, is full time employed and has an average age of 30 years. Most of these users never 
consumed ASS in their childhood. 
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Reviewing the literature, it becomes obvious, that it is impossible to classify ASS users, since they are 
represented in every social class independent of education-level, income-class or childhood. A recent 
meta-analysis including 187 studies aims to obtain an overall lifetime prevalence of ASS misuse 
classified by geographical regions (Sagoe et al., 2014). To get an overview on AAS-use prevalence 
data, an excerpt from this study’s results is shown in Table 2. 
Region N % p 95% CI 
Middle East 7 21.7 13.9- 32.9 
South America 5 4.8 1.2-16.7 
Europe 81 3.8 2.4-5.8 
North America 126 3.0 2.7-3.4 
Oceania 38 2.6 2.1-3.3 
Africa 11 2.4 1.2-4.8 
Asia 1 0.2 0.0-3.5 
Table 2: Prevalence of AAS misuse classified by geographical region is shown.  
N; Number of studies, %p: lifetime prevalence of AAS misuse, 95% CI: 95 % Confidence Interval 
3.1.2 Abuse of AAS - what are the consequences? 
While testosterone is often administered in the clinic (e.g. testosterone replacement therapy due to 
hypogonadism), ASS are normally misused. AAS’s are usually administered in combinations, by either 
“stacking” or “pyramiding” (Hall, 2005). Stacking refers to a practice where two or more ASS are taken 
at the same time (orally, intramuscular or both), while pyramiding is a circular way of ASS intake, 
where doses are gradually increased and then decreased during one cycle. There is no scientific data 
to proof that stacking or pyramiding shows synergism regarding desired effects. Abusers take AAS 
within the gram range, which results in steroid plasma levels that are more than 100 times higher than 
the physiological range.  
Adverse effects can be divided into acute and chronic effects, however, especially for the chronic 
effects, it is difficult to attribute them to one substance, as AAS are usually abused in combination with 
other ASS, with alcohol or with other legal and illegal drugs. The Swedish institute of health and 
national information service installed an anti-doping hotline with its main goal to educate and to 
prevent doping abuse. Eklof et al. summarized information from incoming calls over a 7-year period of 
time (Eklof et al., 2003) and gained valuable information about acute side effects of ASS abuse. The 
ten most commonly reported side effects in males were increased aggressiveness, depression, acne, 
gynecomastia, anxiousness, potency problems, testicular atrophy, sleep disorders, fluid retention and 
mood disturbances. Side effects affecting women included menstruation disturbances, facial hair 
growth, voice deepening and clitoris enlargement (Eklof et al., 2003). All the above listed side effects 
can be explained by over activation of the androgen axis. 
Chronic health consequences associated with AAS abuse include cardiovascular diseases (Kanayama 
et al., 2008). The underlying mechanisms of AAS-induced cardiovascular problems remains poorly 
understood. It was suggested that ASS may be directly toxic to cardiac tissue resulting in 
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cardiomyopathy characterized by impaired systolic and diastolic function. (D'Andrea et al., 2007; 
Kasikcioglu et al., 2009). Second, AAS intake leads to cholesterol dysbalance, it increases low-density 
lipoprotein cholesterol and decreases high-density lipoprotein cholesterol (Glazer, 1991; Hartgens et 
al., 2004; Kouri et al., 1996). Such lipid abnormalities are known to be major risk factors for coronary 
heart disease (Grundy et al., 2004).  
Another well-known adverse effect of AAS is hepatotoxicity including hepatic neoplasm (Sanchez-
Osorio et al., 2008; Socas et al., 2005). Suspected chronic side effects of AAS misuse include prostate 
cancer (Gittes, 1991; Roberts and Essenhigh, 1986) although causality of this is questioned 
(Morgentaler, 2007; Morgentaler, 2006). Further, evidence for adverse renal (Bryden et al., 1995; 
Martorana et al., 1999), immunologic and musculoskeletal effects were reported (Maravelias et al., 
2005; Modlinski and Fields, 2006). 
3.2 Are AAS inhibitors of 11β-hydroxysteroid dehydrogenase 2 and 
may therefore cause cortisol-induced mineralocorticoid receptor 
activation? 
Within the AAS project I tested whether AAS, due to a lack of target specifity, inhibit 11β-HSD2 
dependent glucocorticoid inactivation, which could lead later to MR (over)activation. Cortisol-induced 
MR activation may lead to electrolyte disturbances and therefore contributes to the development of 
hypertension and cardiovascular disease. I tested the inhibitory potential of several different ASS on 
11β-HSD2. For my experiments with radiolabeled cortisone I used HEK-293 cells stably expressing 
11β-HSD2. Potential modulation of the MR activity was studied using transactivation assays. The 
transactivation experiments suggested that fluoxymesterone did not directly module the MR. However, 
experiments in other cell models need to be performed to address the possible contribution of 
transport activity. Testing several ASS, I showed that fluoxymesterone was the most potent inhibitor of 
human 11β-HSD2, inhibiting the enzyme in the low nanomolar range. Furthermore, in LC-MS/MS 
studies, we showed, that fluoxymesterone is a substrate of 11β-HSD2 and is oxidized to 11-
oxofluoxymesterone. 3D-modelling of 11β-HSD2, its endogenous substrate cortisol and 
fluoxymesterone confirmed that fluoxymesterone potently binds to 11β-HSD2 and inhibits the enzyme 
in a competitive manner. Since adverse effects are usually studied in rodents as a next step, I tested 
whether fluoxymesterone would inhibit rat and mouse 11β-HSD2 in vitro. Measurements in rat 
microsomes and in HEK-293 cells stably expressing the murine 11β-HSD2 shows that 
fluoxymesterone inhibited the rodent enzymes about 80-fold less. The results of our study suggested a 
new possible mechanism of ASS induced cardiotoxicity and emphasize on the necessity to carefully 
evaluate animal models with respect to species differences.  
The paper of the above mentioned study forms the basis of this chapter. 
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Anabolic androgenic steroids (AAS) are testosterone derivatives
used either clinically, in elite sports, or for body shaping with the
goal to increase muscle size and strength. Clinically developed
compounds and nonclinically tested designer steroids often
marketed as food supplements are widely used. Despite the
considerable evidence for various adverse effects of AAS use, the
underlying molecular mechanisms are insufficiently understood.
Here, we investigated whether some AAS, as a result of a lack of
target selectivity, might inhibit 11b-hydroxysteroid dehydrogenase
2 (11b-HSD2)–dependent inactivation of glucocorticoids. Using
recombinant human 11b-HSD2, we observed inhibitory effects for
several AAS. Whereas oxymetholone, oxymesterone, danazol, and
testosterone showed medium inhibitory potential, fluoxymesterone
was a potent inhibitor of human 11b-HSD2 (half-maximal
inhibitory concentration [IC50] of 60–100nM in cell lysates; IC50
of 160nM in intact SW-620, and 530nM in MCF-7 cells). Measure-
ments with rat kidney microsomes and lysates of cells expressing
recombinant mouse 11b-HSD2 revealed much weaker inhibition by
the AAS tested, indicating that the adverse effects of
AAS-dependent 11b-HSD2 inhibition cannot be investigated in
rats and mice. Furthermore, we provide evidence that fluoxymes-
terone is metabolized to 11-oxofluoxymesterone by human
11b-HSD2. Structural modeling revealed similar binding modes
for fluoxymesterone and cortisol, supporting a competitive mode of
inhibition of 11b-HSD2–dependent cortisol oxidation by this AAS.
No direct modulation of mineralocorticoid receptor (MR) function
was observed. Thus, 11b-HSD2 inhibition by fluoxymesterone may
cause cortisol-induced MR activation, thereby leading to electrolyte
disturbances and contributing to the development of hypertension
and cardiovascular disease.
Key Words: anabolic androgenic steroid; fluoxymesterone;
testosterone; 11b-hydroxysteroid dehydrogenase; hypertension;
glucocorticoid; cardiovascular disease.
The misuse of anabolic androgenic steroids (AAS) represents
a serious issue both in sports and in specific subsets of the
population (Basaria, 2010). AAS are not only used as ergogenic
drugs by athletes to enhance performance during competition but
also for bodybuilding and for improving body image. Estimates
suggested that the lifetime prevalence of AAS use in the United
States is about 3% and that up to 6% of high school boys and 2%
of girls use AAS (Basaria, 2010; Buckley et al., 1988; Hall,
2005; Kanayama et al., 2009; Yesalis et al., 1997). In addition to
endogenously occurring steroids and synthetic AAS developed
for clinical applications such as muscle wasting in human
immunodeficiency virus infection and aging, an increasing
number of designer steroids that have never been clinically tested
often are present in dietary supplements, mostly without proper
labeling (Kuhn, 2002; Parr and Schanzer, 2010).
The use of AAS has been associated with a series of adverse
effects, including hepatotoxicity, psychological disturbances,
virilization, suppressed spermatogenesis, gynecomastia, as well
as premature mortality mainly as a result of cardiovascular
complications (Handelsman, 2011; Parssinen et al., 2000). AAS
exert direct effects on cardiomyocytes and vascular cells and
indirect effects by decreasing high-density lipoprotein cholesterol
and leading to early abnormalities in blood clotting factors (Ansell
et al., 1993; Calof et al., 2005; Glazer, 1991). An impaired
systolic and diastolic function has been directly associated with
the duration and dose of AAS use in a recent study in power
athletes (D’Andrea et al., 2007). Furthermore, AAS use has been
associated with increased fluid retention and elevated blood
pressure (Sullivan et al., 1998). Despite the recognition of the
serious adverse cardiovascular effects of AAS misuse, the
underlying molecular mechanisms remain largely unknown.
Impaired corticosteroid metabolism and activation of
mineralocorticoid receptors (MR) have been associated with
 The Author 2012. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved.
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cardiovascular disease (Briet and Schiffrin, 2010; Hadoke et al.,
2009; Lastra et al., 2010). Two clinical hallmark studies
supplementing the standard therapy (angiotensin-converting
enzyme inhibitor, loop diuretic, and digoxin) with the MR
antagonists spironolactone (Randomized Aldactone Evaluation
Study, Pitt et al., 1999) or eplerenone (Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival Study,
Pitt et al., 2003b) revealed significantly reduced mortality in
patients with myocardial infarction. Moreover, in patients with
essential hypertension and left ventricular hypertrophy (4E-left
ventricular hypertrophy study, Pitt et al., 2003a), the administra-
tion of the MR antagonist eplerenone lowered blood pressure and
reduced left ventricular hypertrophy. Importantly, aldosterone
levels were low in these patients, suggesting activation of MR by
glucocorticoids, alternative ligands, or ligand-independent receptor
activation (Frey et al., 2004; Odermatt and Atanasov, 2009).
Glucocorticoid-induced MR activation is especially relevant
in situations of impaired activity of 11b-hydroxysteroid
dehydrogenase 2 (11b-HSD2), which converts active 11b-
hydroxyglucocorticoids (cortisol and corticosterone) into their
inactive 11-keto forms (cortisone and 11-dehydrocorticoster-
one) (Frey et al., 2004; Odermatt and Kratschmar, 2012). In
addition to distal colon and renal cortical collecting ducts,
coexpression of 11b-HSD2 and MR has been reported in the
atria and the ventricles of the heart and in endothelial cells and
vascular smooth muscle cells of the aorta (Caprio et al., 2008;
Klusonova et al., 2009; Naray-Fejes-Toth and Fejes-Toth,
2007). Inhibition of 11b-HSD2 is expected to cause excessive
cortisol-induced MR activation in these tissues. The impact of
impaired 11b-HSD2 activity has been investigated in apolipo-
protein E (/)/11b-HSD2 (/) double knockout mice
where the loss of 11b-HSD2 stimulates inflammation and
strikingly promotes atherosclerosis in an MR-dependent
manner (Deuchar et al., 2011). In humans, genetic defects in
the gene encoding 11b-HSD2 result in cortisol-induced MR
activation and severe hypertension, ultimately leading to death
by cardiovascular complications (Ferrari, 2010).
In the present study, we tested the hypothesis that some
widely used AAS compounds might inhibit 11b-HSD2 and/or
directly modulate MR activity.
MATERIALS AND METHODS
Materials. Methenolone was purchased from Cerilliant Corporation (Round
Rock, TX), formebolone from LPB Instituto Farmaceutico S.p.A. (Cinisello,
Milano, Italy), and other steroids from the National Analytical Reference
Laboratory (Pymble, Australia) and from Steraloids (Newport, RI). The reagents
and solvents used were of analytical and high performance liquid chromatography
grade. [1,2,6,7-3H]-cortisol was purchased from PerkinElmer (Waltham, MA). Cell
culture media were purchased from Invitrogen (Carlsbad, CA); all other chemicals
were from Fluka AG (Buchs, Switzerland) of the highest grade available.
Cell culture. HEK-293 cells stably transfected with human 11b-HSD2
(Schweizer et al., 2003), human SW-620 colon carcinoma cells, and human
MCF-7 breast cancer cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum, 4.5 g/l glucose,
50 U/ml penicillin/streptomycin, 2mM glutamine, and 1mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid, pH 7.4.
Determination of inhibition of human and mouse 11b-HSD2 using cell
lysates. The conversion of cortisol to cortisone by 11b-HSD2 was measured
as described previously (Gaware et al., 2011). Briefly, lysates of stably
transfected HEK-293 cells were incubated for 10 min (human 11b-HSD2) or
20 min (mouse 11b-HSD2) at 37C in a total volume of 22 ll of TS2 buffer
(100mM NaCl, 1mM ethylene glycol tetraacetic acid [EGTA], 1mM EDTA,
1mM MgCl2, 250mM sucrose, and 20mM Tris-HCl, pH 7.4) containing a final
concentration of 200nM cortisol, of which 10% was radiolabeled, 500lM
nicotinamide adenine dinucleotide (NADþ), and vehicle or inhibitor at the
desired concentration. Reactions were terminated by adding methanol
containing 2mM unlabeled cortisol and cortisone, followed by separation of
steroids by thin-layer chromatography (TLC) and analysis by scintillation
counting. In addition, the inhibition of the conversion of cortisol to cortisone
and fluoxymesterone to 11-oxofluoxymesterone by human 11b-HSD2 in cell
lysates was assessed by liquid chromatography-mass spectrometry (for LC-MS
method, see below). Lysates of HEK-293 cells stably expressing human 11b-
HSD2 were incubated for 10 min at 37C in a total volume of 500 ll at a final
concentration of 200nM cortisol, 500lM NADþ, and various concentrations of
fluoxymesterone. To assess inhibition of fluoxymesterone oxidation, lysates
were incubated for 1 h at 37C with 500nM fluoxymesterone and various
concentrations of cortisol. Reactions were stopped by shock freezing in a dry
ice-ethanol bath. Stock solutions of all inhibitors were prepared in
dimethylsulfoxide (DMSO) or methanol. Further dilutions were prepared prior
to use in TS2 buffer to yield final concentrations between 0.6nM and 10lM.
Determination of 11b-HSD2 inhibition using rat kidney micro-
somes. Rat kidney microsomes were prepared basically as described earlier
(Senesi et al., 2010). Briefly, the kidneys of male Sprague Dawley rats were
homogenized, and the microsomal fraction was isolated by fractional centrifuga-
tion. The microsomes were resuspended at a protein concentration of 1 mg protein/
ml of buffer containing 100mM NaCl, 1mM EGTA, 1mM EDTA, 1mM MgCl2,
250mM sucrose and 20mM Tris-HCl, pH 7.4, and frozen at 70C. For 11b-
HSD2 activity measurements, microsomes at a final protein amount of 10 lg per
reaction were incubated for 10 min at 37C as described above for cell lysates.
Determination of 11b-HSD2 inhibition in intact SW-620 and MCF-7
cells. 11b-HSD2 activity in intact SW-620 cells was measured as described
earlier (Gaware et al., 2011). Briefly, 100,000 cells per well of a 96-well plate
were incubated in 50 ll steroid-free DMEM containing vehicle or inhibitor at
the desired concentration, 10 nCi radiolabeled cortisol and 50nM unlabeled
cortisol. SW-620 and MCF-7 cells were incubated for 2 and 4 h, respectively, at
37C, followed by separation of steroids by TLC and scintillation counting.
Transactivation assay. HEK-293 cells (200,000 cells per well) were seeded
in poly-L-lysine–coated 24-well plates, incubated for 16 h, and transfected using
calcium phosphate precipitation with pMMTV-lacZ b-galactosidase reporter
(0.20 lg/well), pCMV-LUC luciferase transfection control (0.04 lg/well), and
human recombinant MR (0.35 lg/well). Cells were washed twice with DMEM
6 h posttransfection, followed by incubation for another 18 h to allow sufficient
expression. Cells were then washed once with steroid- and serum-free DMEM
(DMEMsf) and cultivated at least 3 h at 37C. The culture medium was replaced
with fresh DMEMsf containing DMSO (0.05%) or aldosterone (10nM) in the
presence or absence of fluoxymesterone (1lM). After incubation for 24 h, cells
were washed once with PBS and lysed with 60 ll lysis buffer of the Tropix kit
(Applied Biosystems, Foster City, CA) supplemented with 0.5mM dithiothreitol.
Lysed samples were frozen at 80C for at least 20 min. Lysates (20 ll) were
analyzed for b-galactosidase activity using the Tropix kit. Luciferase activity was
analyzed in 20 ll samples using a luciferin solution (Kratschmar et al., 2011).
Measurement of fluoxymesterone metabolism by LC-MS. Lysates of
untransfected HEK-293 cells and HEK-293 cells stably expressing human
11b-HSD2 were incubated for 1 h at 37C in a total volume of 500 ll at a final
concentration of 1lM fluoxymesterone or cortisol and 500lM NADþ. The
reactions were stopped by shock freezing using a dry ice-ethanol bath.
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After thawing, samples were centrifuged at 4C for 10 min at 500 3 g and
supernatants transferred onto a solid phase extraction column (Oasis HBL 1 cc
[30 mg] Waters WAT094225) preconditioned with 1 ml of methanol and 1 ml
of distilled water. After washing twice with 1 ml of water, steroids were eluted
by twice adding 1 ml of methanol. The combined eluate was evaporated to
dryness and reconstituted with 100 ll of methanol.
Steroids were resolved on an Atlantis T3 (3 lm, 2.1 3 150 mm) column
(Waters, Milford, MA) at 30C using an Agilent model 1200 Infinity Series
chromatograph (Agilent Technologies, Basel, Switzerland). The mobile phase
consisted of solvent A (0.1% formic acid in water) and solvent B (0.1% formic
acid in acetonitrile). To separate fluoxymesterone and 11-oxofluoxymesterone,
a linear gradient starting from 55% solvent A and 45% solvent B to 5% solvent
A and 95% solvent B from 0 to 12 min was used. To separate cortisol and
cortisone, a linear gradient starting from 85% solvent A and 15% solvent B to
60% solvent A and 40% solvent B from 0 to 15 min was used. The flow rate
was maintained at 0.4 ml/min.
The LC was interfaced to an Agilent 6490 triple Quad mass spectrometer (MS).
The MS was operated in atmospheric pressure electrospray positive ionization
mode, with nebulizer pressure and nebulizer gas flow rate of 45 psi and 10 l/h,
respectively, a source temperature of 350C and capillary and cone voltage of 4
kW and 190 V, respectively. Data acquisition was performed by Mass Hunter
workstation (Version B01.04). Metabolites were identified by comparing their
retention time and mass to charge ratio (m/z) with those of authentic standards.
Qualitative determination of steroids was performed by selected positive
ionization multiple reaction monitoring. Fluoxymesterone (m/z 337.1) and
11-oxofluoxymesterone (m/z 335.1) eluted at 9.1 and 9.7 min, respectively. For
the quantitative determination of fluoxymesterone, prednisolone (m/z 361.1,
retention time 7.3 min) was used as internal standard. Metabolites were quantified
from calibration curves of the ratio of the peak area of the authentic
fluoxymesterone standard and the internal prednisolone standard incubated with
lysates of untransfected HEK-293 cells at a total protein concentration identical to
that of the experimental setting and plotted against the concentration of authentic
standards (normalization to the internal standard). A reference standard for
11-oxofluoxymesterone was not available and needs to be synthesized for
confirmation of the structure and exact quantification. Cortisone (precursor and
product ion at m/z 361 and 163) and cortisol (precursor and product ion at m/z
363 and 121) eluted at 8.5 and 8.9 min, respectively.
Determination of the binding mode of steroids in 11b-HSD2 by molecular
modeling. The 2D structures of fluoxymesterone, testosterone, cortisone, and
cortisol were generated using ChemBioDraw Ultra 12.0 (CambridgeSoft, U.K.,
1986–2009, www.cambridgesoft.com). Two-dimensional structures were trans-
formed into 3D using CORINA (Molecular Networks GmbH, Erlangen,
Germany). These four compounds were docked into the previously generated
homology model of 11b-HSD2 (Gaware et al., 2011) using GOLD (Jones et al.,
1997; Verdonk et al., 2003). The binding site was defined by a 10 A˚ sphere with
the hydroxyl group of Tyr232 in the center. To optimize the ligand orientation,
two protein hydrogen bond constraints were defined: one to the catalytically
active Tyr232 and the second one to Tyr226. During the docking, the protein was
handled as rigid and ligands as flexible. The ligand flexibility was increased by
allowing the ring corner to flip. GoldScore was used as a scoring function, and 10
docking solutions for each ligand were calculated. Atom types for the protein as
well as for the ligands were automatically determined by the program.
LigandScout (Wolber and Langer, 2005) was used for visualizing the docking
results and for the analysis of the protein-ligand interactions.
RESULTS
Inhibition of 11b-HSD2 by Anabolic Androgenic Steroids
Measured in Cell Lysates
In order to test the hypothesis that AAS might cause adverse
effects by disrupting corticosteroid hormone action, we tested
several frequently used AAS for potential inhibition of the 11b-
HSD2–dependent conversion of cortisol to cortisone as well as
for their impact on MR transactivation. The activity of human
11b-HSD2 was assessed using lysates of stably transfected
HEK-293 cells and by determining the conversion of radio-
labeled cortisol to cortisone. At a high concentration (10lM),
only norbolethone and methenolone did not have any inhibitory
effect (Table 1). Dehydroepiandrosterone, mesterolone, and
formebolone showed weak inhibitory effects with estimated
Half-maximal inhibitory concentration (IC50) values of 10lM or
higher. For the compounds that showed less than 40% remaining
activity at this concentration, IC50 values were determined. This
revealed potent inhibition by the 11b-hydroxylated steroid
fluoxymesterone with IC50 of 60 ± 27nM and medium inhibitory
effects for testosterone (Fig. 1A), oxymesterone, danazol, and
oxymetholone. The inhibition of 11b-HSD2–mediated cortisol
oxidation by fluoxymesterone was confirmed in an assay using
unlabeled cortisol and quantification of the product cortisone by
LC-MS. A slightly higher IC50 value of 100 ± 28nM was
obtained (data not shown).
Adverse effects are usually studied in a next step in
rodents. In preparing for animal studies, we tested whether
fluoxymesterone would inhibit rat and mouse 11b-HSD2
in vitro. Measurements with rat kidney microsomes revealed
an approximately 80-fold lower inhibitory potential with an
IC50 of 4.9 ± 0.8lM (Fig. 1B). Similarly, an IC50 of 5.4 ±
0.4lM was obtained for fluoxymesterone inhibition of 11b-
HSD2 using lysates of HEK-293 cells stably expressing the
mouse enzyme (Fig. 1C). Testosterone was about 10-fold less
potent toward the rat and the mouse enzymes with IC50 of
14.9 ± 4.3 and 15.3 ± 3.5lM, respectively. The weak
TABLE 1
Inhibition of 11b-HSD2 by Anabolic Androgenic Steroids
Compound
Remaining cortisol
to cortisone
conversion at 10lM (%) IC50 (nM)
Glycyrrhetinic acid 2.4 ± 1.8 256 ± 33a
Testosterone 12 ± 12 1370 ± 60
Dehydroepiandrosterone 78 ± 12b nd
Danazol 23 ± 17 740 ± 110
Fluoxymesterone 1.9 ± 1.5 60 ± 27
Formebolone 51 ± 12 nd
Mesterolone 74 ± 6 nd
Methenolone 90 ± 3 nd
Norbolethone 92 ± 13 nd
Oxymesterone 2.6 ± 3.5 960 ± 140
Oxymetholone 6.4 ± 4.5 710 ± 50
Notes. The 11b-HSD2–dependent conversion of cortisol (50nM) to cortisone
was measured in cell lysates in the presence of 500lM of NADþ and various
concentrations of AAS or vehicle (0.1% DMSO). Glycyrrhetinic acid was
included as reference compound. Inhibitory activities represent IC50 ± SD from
at least three independent experiments. nd, not determined.
aValue taken from Kratschmar et al. (2011).
bDetermined at 20lM.
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inhibitory effects of fluoxymesterone and testosterone on the
rodent 11b-HSD2 enzymes make it unlikely to study the
adverse effects in these species, and animal experiments were
not performed.
Inhibition of 11b-HSD2 in Intact SW-620 and MCF-7 Cells
The effect of fluoxymesterone on 11b-HSD2 activity was
next determined in intact cells. Two distinct cell models,
human colon carcinoma SW-620 cells and human breast
cancer MCF-7 cells with relatively high endogenous expres-
sion of the enzyme were applied. Cell models with lower
expression may not be suitable to determine direct effects
on enzyme activity due to interference with altered gene
expression. Fluoxymesterone potently inhibited 11b-HSD2 in
a concentration-dependent manner with IC50 of 160 ± 10nM
in SW-620 cells and IC50 of 530 ± 70nM in MCF-7 cells
(Fig. 2). Although the known reference compound glycyr-
rhetinic acid also showed potent inhibition, testosterone did
not significantly inhibit 11b-HSD2 at concentrations up to
10lM in intact SW-620 or MCF-7 cells.
Fluoxymesterone Does Not Directly Modulate MR Activation
To see whether fluoxymesterone might directly modulate MR
activity, transactivation assays in HEK-293 cells transiently
expressing MR and a galactosidase reporter under the control of
the mouse mammary tumor virus promoter were performed. Cells
were incubated with 1lM of fluoxymesterone alone or together
with 10nM aldosterone. The reporter gene response was
indistinguishable if cells were treated with either aldosterone
alone or in combination with fluoxymesterone (Fig. 3).
Furthermore, basal receptor activity measured by DMSO
treatment (0.05%) was not changed by fluoxymesterone.
Similarly, the other tested AAS (see Table 1) did not activate
or antagonize MR function, indicating that these steroids have no
direct effect on the receptor.
Fluoxymesterone Is Metabolized by 11b-HSD2
Because fluoxymesterone possesses an 11b-hydroxyl group,
we hypothesized that this steroid may be a substrate and
therefore competitively inhibit the enzyme. Therefore, we
established an LC-MS–based method using the multiple
FIG. 1. Inhibition of 11b-HSD2 activity by fluoxymesterone measured in cell lysates. (A) Lysates of HEK-293 cells stably expressing recombinant human
11b-HSD2 were incubated for 10 min at 37C with 50nM of radiolabeled cortisol and increasing concentrations of fluoxymesterone (squares) or testosterone
(circles), followed by determination of cortisone formation. Similarly, inhibition by fluoxymesterone and testosterone was measured using rat kidney microsomes
(B) and lysates of HEK-293 cells stably expressing mouse 11b-HSD2 (C). Values were normalized to the activity observed in the presence of vehicle (0.1%
DMSO). Data represent mean ± SD from three independent experiments.
FIG. 2. Inhibition of 11b-HSD2 activity by fluoxymesterone in intact SW-620 and MCF-7 cells. Intact SW-620 and MCF-7 cells, with endogenous expression
of 11b-HSD2, were incubated for 2 and 4 h, respectively, with 50nM of radiolabeled cortisol and increasing concentrations of fluoxymesterone. Values were
normalized to the activity observed in the presence of vehicle (0.1% DMSO). Data represent mean ± SD from three independent experiments.
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reaction monitoring mode for the qualitative and quantitative
determination of fluoxymesterone (m/z 337.1) and its metabolite
11-oxofluoxymesterone (m/z 335.1) (see Materials and Methods
section). Fluoxymesterone and 11-oxofluoxymesterone were
clearly separated with retention times of 9.1 and 9.7 min,
respectively (Fig. 4). Similarly, conditions were established to
separate and quantify cortisol (m/z 363, retention time 8.5 min)
and cortisone (m/z 361, retention time 8.9 min). Upon incubation
for 1 h with lysates of HEK-293 cells stably expressing
11b-HSD2, approximately 50% of the supplied fluoxymesterone
(1lM) was converted. In comparison, under the same conditions,
approximately 80% of cortisol was converted. No conversion
was observed when lysates of untransfected HEK-293 cells were
used. Thus, although both steroids are substrates of 11b-HSD2
(Fig. 5), the enzyme more efficiently oxidizes cortisol.
To further support the hypothesis that fluoxymesterone and
cortisol bind to and are metabolized by 11b-HSD2, we studied
the impact of cortisol on the conversion of fluoxymesterone (at
a final concentration of 500nM) to 11-oxofluoxymesterone in
cell lysates. A concentration-dependent inhibition with an IC50
of 730 ± 190nM was obtained (data not shown).
Comparison of the Binding Mode of Steroids in 11b-HSD2
All four compounds were docked into the 11b-HSD2 active
site. They were all positioned in the vicinity of the catalytic
residue Tyr232, close to the catalytic triad Ser219-Tyr232-
Lys236 (Fig. 6A). The binding interactions of each compound
were investigated in detail to explain the difference in their
activities. The automatically created pharmacophoric interac-
tion pattern showed different hydrogen-bonding patterns for
each compound (Figs. 6B–E).
The natural ligand cortisol was predicted to have favorable
binding interactions. The 11b-hydroxy group interacts with the
FIG. 3. Effect of fluoxymesterone on MR transactivation. HEK-293 cells
were transfected with pMMTV-LacZ reporter, pCMV-LUC control plasmid,
and human MR expression plasmid. Cells were incubated for 24 h in the
presence or absence of 10nM aldosterone with or without 1lM fluoxymester-
one, followed by determination of galactosidase and luciferase activities.
Galactosidase reporter activity was normalized to the internal luciferase control.
Data were normalized to vehicle control (0.05% DMSO) and represent mean ±
SD from a representative experiment performed in triplicate.
FIG. 4. Representative LC-MS chromatogram showing the metabolism of
fluoxymesterone and cortisol by 11b-HSD2. Lysates of untransfected HEK-293
cells (A and C) and lysates of 11b-HSD2–expressing HEK-293 cells (B and D)
were incubated for 2 h with 1lM of fluoxymesterone (A and B) or cortisol
(C and D), followed by analysis of steroid metabolites by LC-MS. The area
under the peak of the substrate is indicated in black and that of the product in
white color. Fluoxymesterone (m/z 337) eluted at 9.1 min and
11-oxofluoxymesterone (m/z 335) at 9.7 min. Cortisol (m/z 363, 121) eluted
at 8.5 min and cortisone (m/z 361) at 8.9 min.
FIG. 5. Structures of 11b-HSD2 substrates and products.
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catalytic residue Tyr232, and the ligand was anchored to the
binding pocket with three other hydrogen bonds. The interaction
pattern of cortisone, the end product of the reaction catalyzed by
11b-HSD2, differed to the one of cortisol in terms that the
product moved the 11-keto group away from the catalytically
active residues. The most active inhibitor, fluoxymesterone, was
observed to be anchored to the binding pocket with four
hydrogen bonds. The hydrogen bonds between Tyr232, Ser219,
FIG. 6. Modeling of the binding of steroids to 11b-HSD2. (A) Cortisol (blue), cortisone (green), fluoxymesterone (red), and testosterone (gray) docked into
the ligand-binding pocket of 11b-HSD2. The catalytic triad as well as other amino acid residues with which common interactions were observed are depicted in
ball and stick style. (B–D) Two-dimensional representations of the binding interactions of steroids with 11b-HSD2. Binding interactions of cortisol (B), cortisone
(C), fluoxymesterone (D), and testosterone (E) with 11b-HSD2 are shown. The hydrophobic interactions are represented in yellow, hydrogen bond acceptors in
red, and hydrogen bond donors in green.
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and the 11-hydroxy group of fluoxymesterone indicated that this
molecule can be transformed into its 11-keto form by the enzyme.
In fact, biological data showed that fluoxymesterone is a substrate
of 11b-HSD2, but with a lower conversion rate than cortisol. This
lower conversion rate leads to a competitive inhibition of 11b-
HSD2 by fluoxymesterone.
Interestingly, testosterone was predicted to adapt a different
binding mode compared with the other three compounds.
It was located in the same area as the others; however, it had
a flipped binding mode. Whereas cortisol, cortisone, and
fluoxymesterone had their 3-keto groups pointing toward
Tyr226, the 3-keto group of testosterone superimposed onto
position 17 of the other steroids. No other hydrogen bond
between testosterone and the protein was observed. This
kind of binding mode as well as fewer hydrogen bonds
and hydrophobic interactions with the protein could be
an explanation for the weaker 11b-HSD2 inhibition of
testosterone.
DISCUSSION
In this study, we analyzed several well-known and widely
used AAS for their potential to inhibit 11b-HSD2 and
identified fluoxymesterone as a potent inhibitor. The IC50
values of 60–100nM in cell lysates and 160 and 530nM
measured in intact SW-620 and MCF-7 cells, respectively, are
in a comparable range with the inhibitory potential of
glycyrrhetinic acid, which has been demonstrated in both
animals and humans to inhibit 11b-HSD2 and cause
glucocorticoid-mediated MR activation, potassium excretion,
sodium and water retention, and increased blood pressure
(Ferrari, 2010; Ferrari et al., 2001; Serra et al., 2002). As
shown for fluoxymesterone in the present study, glycyrrhetinic
acid also does not directly modulate MR function
but competitively inhibits 11b-HSD2, thereby leading to
glucocorticoid-mediated MR activation.
Oral fluoxymesterone, which is marketed as halotestin in the
United States for the treatment of hypogonadism in men and of
certain hormone-dependent mammary tumors in women, can
exacerbate health states where edema plays important
roles, such as congestive heart failure (as described in the
package leaflet, http://www.pfizer.com/files/products/uspi_
halotestin.pdf). A possible mechanistic explanation for these
warnings concerning fluid retention states includes the
involvement of MR activation. Following oral administration,
fluoxymesterone is rapidly metabolized in the liver. The
adverse effects described above can be expected to be much
more pronounced upon intravenous application of the drug,
which is the preferred route of administration in sports and
bodybuilding.
Inhibition of 11b-HSD2 in the renal distal tubules and cortical
collecting ducts results in glucocorticoid-induced MR activation
with subsequently increased activities of Naþ/Kþ-ATPases at the
basolateral membrane and of Naþ channels (ENaC) on the apical
membrane of epithelial cells, resulting in potassium excretion
and sodium and water retention (Ferrari, 2010). In the
vasculature, decreased 11b-HSD2 activity leads to vasoconstric-
tion and elevated blood pressure, probably by a mechanism
involving the activation of glucocorticoid receptor rather than
MR (Goodwin et al., 2008). Furthermore, inhibition of 11b-
HSD2 in vascular smooth muscle cells and endothelial cells of
the heart may lead to paracrine activation of MR in
cardiomyocytes. In a recent study using transgenic mice,
Deuchar et al. (2011) showed that the ablation of 11b-HSD2
in apolipoprotein E knockout mice aggravated the progression of
atherosclerosis by a mechanism involving MR activation and
stimulation of inflammation in the vascular endothelium. The use
of AAS has been associated with reduced levels of high-density
lipoproteins and an increased ratio of low-density lipoproteins to
high-density lipoproteins (Glazer, 1991; Thompson et al., 1989).
Thus, AAS that inhibit 11b-HSD2, like fluoxymesterone, may
be especially prone to cause adverse cardiovascular effects.
Regarding the inhibitory mechanism, both the 3D structural
modeling and the fact that 11b-HSD2 can metabolize
fluoxymesterone to 11-oxofluoxymesterone support a compet-
itive inhibition of cortisol oxidation. The 11b-hydroxyl on
fluoxymesterone has important stabilizing interactions that are
absent in testosterone and other AAS. Interestingly, formebo-
lone also has an 11b-hydroxyl but is a very weak 11b-HSD2
inhibitor, probably as a result of the methyl group in ring-A,
which leads to steric hindrance and prevents optimal
stabilization in the binding pocket. Although 11b-HSD2 can
oxidize fluoxymesterone at position 11, this reaction represents
a minor contribution to the overall metabolism of this steroid
(Pozo et al., 2008). Compared with cortisol, fluoxymesterone
was approximately three to five times less efficiently converted
to its 11-oxo form, resembling the conversion of dexametha-
sone, which also has a fluor atom at position 9 (Rebuffat et al.,
2004). A reference compound needs to be synthesized to test
whether 11b-HSD2 might be able to reduce 11-oxofluoxymes-
terone as previously observed for 11-oxodexamethasone. This,
together with the extensive hepatic metabolism, would explain
why 11-oxo derivatives of fluoxymesterone are minor
metabolites of fluoxymesterone in human urine (Pozo et al.,
2008).
The potent inhibition of human but not rat and mouse
11b-HSD2 by fluoxymesterone emphasizes the importance to
assess species-specific differences using recombinant enzymes
and enzyme preparations from native tissues before conducting
animal studies, both from an ethical point of view and to save
resources. Clinical studies will need to investigate the potential
of fluoxymesterone to inhibit 11b-HSD2 activity in vivo. This
can be achieved by measuring its impact on the ratio of
11b-hydroxy- to 11-oxoglucocorticoids in plasma and their
corresponding tetrahydro metabolites in 24-h urine samples
and by examining the patients for the presence of low-renin and
low-aldosterone hypertension.
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3.4 Further results and outlook concerning 11β-hydroxysteroid 
dehydrogenase type 2 inhibition by androgenic steroids 
3.4.1 Androstenedione potently inhibits 11β-hydroxysteroid dehydrogenase type 2 
The AAS project started by a screening of different steroids and determination of their IC50 against 
11β-HSD2. In addition to synthetic compounds, the inhibitory potential of several endogenous steroids 
was determined. The results are shown in Table 1 of the fluoxymesterone study (Furstenberger et al., 
2012). An important observation not shown and not discussed in this study is the high inhibitory 
potential of the endogenous steroid androstenedione. Androstenedione was shown to inhibit 11β-
HSD2 with an IC50 in the low nanomolar range (Figure 7).  
 
 
 
 
 
 
 
Figure 7: Conversion of cortisone to cortisone upon androstenedione incubation.  
The potent inhibition of 11β-HSD2 by androstenedione could only be shown in lysates of HEK-293 
cells stably expressing 11β-HSD2. However, in intact cells, no relevant inhibitory effect of 11β-HSD2 
could be detected. We know from previous studies carried out in our group (Nashev et al., 2010) that 
androstenedione is able to penetrate the cell membrane of HEK-293 cells. Nashev et al. measured the 
17β-HSD3 mediated conversion of androstenedione to testosterone in HEK-293 cells transiently 
expressing 17β-HSD3. Furthermore, the conversion of androstenedione to testosterone could be 
inhibited by using the UV-filter benzophenone-1.  This raises the question why androstenedione only 
inhibits 11β-HSD2 in cell lysates where the enzyme is directly accessible. The most obvious difference 
in our experimental setting compared to the experiments by Nashev et al. was the transfection 
conditions of the cell line. It has been shown that transfection and medium conditions may alter the 
expression of transport proteins in HEK-293 cells (Ahlin et al., 2009). Consequently, we repeated the 
experiment in transiently transfected cells. However, the outcome did not differ from the original 
experiment. Androstenedione showed no relevant inhibitory potential towards 11β-HSD2. We decided 
to test another cell line and repeated the experiment using SW-620 cells, a human colon 
adenocarcinoma cell endogenously expressing 11β-HSD2. Unfortunately, we could also not detect 
any inhibition of 11β-HSD2 upon incubation with androstenedione. In summary, we observed a very 
potent inhibition by the endogenous steroid androstenedione of the 11β-HSD2 dependent cortisol 
inactivation in cell lysates, but we are unable to confirm this inhibitory effect in intact cells. What 
experiments need to be performed to evaluate whether the inhibition might be important in vivo? If 
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inhibition of 11β-HSD2 occurs in vivo, subsequent cortisol-induced MR activation might play a role in 
the development and progression of hypertension. Possible reasons for the lack of inhibition in intact 
cells could be due to rapid androstenedione efflux from the cells mediated by transport proteins. A 
study performed in different commonly used cell lines focuses on the expression profiles of important 
xenobiotica-transporting proteins (Ahlin et al., 2009). Though Ahlin et al. suggests that HEK-293 cells 
express a relatively low amount of transport proteins compared with other cell lines (such as for 
example CaCo-2 cells),they could still identify 21 drug transporters expressed in HEK-293 cells. In 
future studies, it will important, therefore, to inhibit specific transporters to see whether they play a 
relevant role in androstenedione efflux. Due to distinct species differences in steroid induced 11β-
HSD2 inhibition (described before (Furstenberger et al., 2012)), in vivo rodent experiments might not 
be meaningful and translational relevance to humans may be poor. To investigate whether the 
androstenedione induced 11β-HSD2 inhibition is relevant in vivo and might have an influence on 
subsequent MR activation, a humanized mouse might provide useful data. Additionally, a clinic study 
with administration of androstenedione and analysis of plasma samples for the ratio of cortisol to 
cortisone would help to further test for cortisol-induced MR activation. 
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4. Project 2: Evaluation of testosterone production in Leydig cell 
models and characterization of current methods by measuring 
androgen levels 
4.1 Introduction to endogenous androgens 
Most androgens mediate their actions through the androgen receptor (AR), which belongs to the 
superfamily of the steroid/thyroid hormone nuclear receptors. The AR acts as a ligand inducible 
transcription factor (Mangelsdorf et al., 1995). Testosterone and the more potent DHT are the two 
native ligands of the AR. Ligand-AR complexes bind as homodimers to androgen responsive elements 
(ARE) in target gene promoters. Consensus ARE are composed of two core 5′-AGAACA-3′ motifs 
separated by a space of three base pairs (Khorasanizadeh and Rastinejad, 2001). Testosterone is the 
most extensively studied androgen, however, serum levels show large variations, both within different 
organisms but also within the same organism depending on health and age. Furthermore, testosterone 
levels are also influenced by a multitude of factors such nutrition and the circadian rhythm (Deslypere 
and Vermeulen, 1984). Research focusing on the different factors that influence testosterone levels 
and their subsequent impact on disease development is a competitive field. Investigations in relation to 
testosterone levels include psychological stress (Bhongade et al., 2014), seasonal variations (Smith et 
al., 2013), autoimmune diseases (Costa et al., 2014), anorexia (Smiarowska et al., 2014) and various 
types and stages of cancers (Orsted et al., 2014; Thomas et al., 2014). To conclude, the levels of 
testosterone show broad inter-individual variations and therefore clinical values need to be evaluated 
within the context of the specific physiological and psychological state of the individual. 
DHT is a much more potent AR ligand than testosterone. DHT is formed in endocrine tissues 
(prostate, skin, hair follicles) from androstenedione via testosterone (front-door pathway) or via 5α-
androstanedione (back-door pathway) (Luu-The, 2013). Another source of serum DHT is the liver, 
which also expresses steroidogenic enzymes at high levels (Shores et al., 2014). DHT levels are 
roughly 3-5% of the testosterone levels. Although testosterone and DHT both bind to the AR, the 
downstream response is not always identical and this may be due to changes of the quaternary 
structure of the AR upon binding testosterone or DHT (Baek et al., 2006). Androstenedione is 
predominately produced in the testis (in women in the ovaries) by 3β-HSD-mediated conversion from 
DHEA. 3β-HSD is much more effective in converting androstenedione from DHEA than 17β-HSD3 is 
converting testosterone from androstenedione, suggesting that the formation of the inactive precursor 
androstenedione does not represent the rate-limiting step, but rather that it is produced in excess 
(Luu-The, 2013).  
Dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS are the most abundant steroids in 
humans (Davis et al., 2011), with plasma concentrations in the micromolar range. DHEA is produced 
from cholesterol mainly in the adrenals but also in the testis, the ovaries, skin, and brain (Davis et al., 
2011; Zouboulis et al., 2007). Most of the DHEAS is loosely bound to the plasma protein albumin 
(Panjari and Davis, 2007). Currently, no specific high affinity plasma binding protein has been 
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identified (Legrain et al., 2000). DHEA but not DHEAS is bound by the sex hormone binding globulin 
(Panjari and Davis, 2007). DHEA supplementation combined with gonadotropin is used in reproductive 
medicine as a way to treat female infertility (Casson et al., 2000). There is evidence that low serum 
levels of DHEA correlate with coronary heart disease, however, there is not sufficient data to show that 
DHEA supplementation would have any cardiovascular benefit (Thijs et al., 2003).  
A key feature of steroids is their ability to tightly regulate physiological functions. Small changes in 
systemic/ local steroid concentrations allow steroids to switch on or off physiological processes. Table 
3 gives a general overview on the magnitude of concentrations and variations of abundant steroids in 
human plasma. 
Testosterone 
Male prepuberty 0 - 1 nmol/l  (Albin and Norjavaara, 2013) 
Male pubertal 7 - 13 nmol/l  (Albin and Norjavaara, 2013) 
Male < 60 years 15.9 - 29.8 nmol/l  (Deslypere and Vermeulen, 1984) 
Male > 60 years 11.5 - 22.6 nmol/l  (Deslypere and Vermeulen, 1984) 
Female premenopausal 1.3- 2.9 nmol/l (Davison et al., 2005) 
Female postmenopausal 0.2- 2.0 nmol/l  (Davison et al., 2005) 
Androstenedione 
Male adult 1.39-5.23nmol/l (Rosenfield and Otto, 1972) 
Female adult 1.05- 6.94 nmol/L (Burger, 2002) 
Dihydrotestosterone 
(DHT) 
Male adult 0.6-2.4 nmol/l  (Muller et al., 2012) 
Female adult 0.1-1.0 nmol/l (Burger, 2002) 
Dehydroepiandrosterone 
(DHEA) 
Male adult 2.07- 4.87 µmol/l (Landt et al., 2011) 
Female adult 0.3- 12.5 µmol/l (Davison et al., 2005) 
Table 3: Overview of the most abundant steroids and their plasma concentrations.  
4.2 Technical methods of steroid measurements 
Lack of standardized steroid hormone quantification assays are a major limitation in steroid research 
(Stanczyk et al., 2007). It is difficult to reliably compare steroid concentrations between different 
studies that have been measured using different methods. Steroid measurements (in plasma or in 
other matrices) pose various challenges:  
- Steroid concentrations vary depending on age, gender and health status (Rosner et al., 2007). 
- Steroids are very difficult to specifically identify in biochemical assays, since their structures 
and their chemical properties are very similar. 
- Steroids in plasma are both free or protein bound and it is questioned whether total or free 
steroid is the more useful measurement. 
- There are generally no age- or gender-corrected reference values for steroids measurements 
in clinical applications. 
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There are only a few methods available for the measurement of steroids and/or steroidogenic 
metabolism. The two most commonly used methods are immunoassay and mass spectrometry.  
4.2.1 Immunoassays 
Immunoassays are the most widely used method to measure steroids. Currently, the popular 
immunoassay of choice is the enzyme linked-immunosorbant assays (ELISA). However, the majority 
of our knowledge about the physiological roles of steroids in humans derive from studies in which 
circulating  steroid hormones were measured by Radioimmunoassay (RIA) (Stanczyk et al., 2007). 
Since RIAs generate radioactive waste, they have become less popular (Rosner et al., 2007). 
Immunoassays can be carried out either directly without sample preparation, or following extraction 
and chromatographic separation of the steroids. The latter technique is more advantageous, since it 
allows the measurement of multiple steroids from a single sample. Generally, immunoassay 
measurements are more accurate and sensitive if the steroids are separated and purified prior to the 
measurement. However, such protocols are often labor intensive, time consuming, expensive and due 
to the complexity of the sample preparation, may increase the probability of human error. For steroid 
measurements, commercially available kits are used either in conjunction with an automated 
instrument or manually processed. The limit of quantification for testosterone in commercialized kits 
varies depending on the supplier and can reach the low picogramm/ml range (for example: Enzo life 
science; 5.67 pg/ml; Cayman; 6 pg/ml; Biovendor Research and Diagnostic Products: 22 pg/ml; 
Abcam: 70 pg/ml (limit of quantification as indicated by the manufacturer)). Commercially 
manufactured immunoassay kits are technically simple to carry out and relatively fast. However, both 
the kit manufacturer and the testing laboratory rarely thoroughly validate the assay method (Stanczyk 
et al., 2003). Several studies evaluating the reliability of testosterone measurements with commercial 
kits have been carried out. These studies focused on the impact of different matrices which may result 
in an over- or underestimation of the testosterone levels (Wheeler et al., 1996). They also compare 
immunoassays with other methods such as gas chromatography (Fitzgerald and Herold, 1996) or RIA 
(Boots et al., 1998) and finally, determine the precision of intra- and inter-assay measurements (Boots 
et al., 1998; Stanczyk et al., 2003). Generally, it can be concluded that there are marked variations 
between the kits from different manufacturers, and that a remarkable number of kits do not fulfill all the 
specifications given by the manufacturer (Stanczyk et al., 2007).  
4.2.2 Mass spectrometry 
For the MS measurement of steroids, either gas (GC) or liquid chromatography (LC) methods are 
used for the initial separation of steroids (Rosner et al., 2007). The main advantage of mass 
spectrometry is that the steroids can be both identified and quantified. MS is also remarkably accurate, 
as long as the assay is thoroughly validated. However, MS methods are relatively expensive, time 
consuming and require considerable expertise. Despite these challenges, MS is a much preferred 
method in the steroid field. MS methods developed for routine measurements are very popular (Owen 
et al., 2013) and sophisticated new methods are published frequently (Keevil, 2013; Singh et al., 
2014). 
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4.3 Overview of the testis and testicular cell types 
The human testis is an ellipsoidal paired organ located in the scrotum. The two testicles are enclosed 
by connective tissue capsules for protection. Multiple connective tissue septums divide the testicular 
tissue in 250-350 lobes called the lobuli testi. These lobuli testi contain spiral winded tubules, the 
seminiferous tubules. The seminiferous tubules are protected by connective tissue and open into the 
rete testis, which is a network of tubules located in the hilum of the testicle (mediastinum testis) in the 
basal side of the testicle. About 10 efferent ductules are formed from the rete testis and open into the 
semen ducts (Thews, 1999). The inner walls of the seminiferous tubules are predominately 
constructed from Sertoli cells which nourish the germ cells and guide them through their development 
from spermatogonim to spermatozoon. Sertoli cells control this process by producing androgen 
binding protein that can bind testosterone, DHT and the estrogen estradiol, all of which are needed for 
spermatogenesis (Gershagen et al., 1989; Kaur et al., 2014). The outer wall of the seminiferous 
tubules is formed by peritubular myoid cells. In the interstitial space in between the tubules, the 
androgen producing Leydig cells are located (Thews, 1999). Besides the Leydig cells, there are blood 
capillaries and cells of the immune system present in the interstitium. Figure 8 gives an overview of 
the anatomy of the testis and of the different cell types present in testicular tissue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Anatomical structures and cell types of the human testis (Picture modified from Pearson’s 
Education Inc. and Kaur (Kaur et al., 2014), with permission from Elsevier 
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4.4 Pathways involved in androgen formation – front-door versus 
back-door  
The AR conducts pleiotropic physiological functions on one side, but also plays an important 
pathological role in various types of cancers such as breast or prostate cancer (Giovanni Luca et al., 
2013; Helsen et al., 2014). The use of the AR as a therapeutic target against cancer is the focus of 
many research groups worldwide. To understand AR activation, it is crucial to elucidate the 
mechanisms and pathways by which its ligands, testosterone and DHT are formed. For decades, it 
was generally thought that the potent AR ligand DHT is formed by testosterone reduction catalyzed by 
5α-reductase (Wilson and Walker, 1969). This hypothesis was mainly supported by the fact that 46, 
XY DSD (also referred to as pseudo hermaphroditism, a disorder where AR activation is strongly 
impaired) is caused by testicular 17β-HSD3 deficiency (Wilson, 1975). In patients with 17β-HSD3 
deficiency, minimal testosterone is formed. However, studies using the human sebaceous gland cell 
line SZ95 and the human prostate cancer cell line DU-145 suggest that testosterone does not need to 
be the intermediate metabolite in the formation of DHT (M. Samson, 2010; Samson et al., 2010). 
Additionally, the pathway of reducing androstenedione to androstanedione is thermodynamically more 
favorable, since 5α-reductase binds androstenedione with a higher affinity than it binds testosterone 
(Andersson and Russell, 1990). Auchus (Auchus, 2004) was the first to describe a pathway in which 
DHT is produced from the inactive precursor androstanediol in tammar wallybies (Wilson et al., 2003). 
Auchus introduced the term “back-door” pathway to describe a new, alternative testosterone 
independent pathway to produce DHT. A lot of research has been carried out to validate the back-door 
pathways and there still remain many open questions. For example whether 5α-reduced C21 steroids 
are transformed to androsterone in humans (Attard et al., 2012; Kamrath et al., 2012) and whether 5α-
androstenediol is produced from androstenedione or testosterone in vivo (Mahendroo et al., 2004; 
Wilson et al., 2003). Figure 9 (Luu-The, 2013) gives an overview of the front- and back-door pathways 
according the current knowledge.  
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Figure 9: Diverse front- and back-door pathways were identified so far. The thickness of the arrows 
represents the relative importance of the reaction. Figure used with the permission of Elsevier. 
(3α-diol : 5α-androstane-3α,17β-diol ; 3α-diol-G : 5α-androstane-3α,17β-diol glucuronide ; 3α-HSD : 
3α-hydroxysteroid dehydrogenase, 3β-diol :  5α-androstane-3β,17β-diol ;3β-diol-G : 5α-androstane-
3β*17β-diol glucuronide ; 3β-HS : 3β-hydroxysteroid dehydrogenase ; 4-dione: 4-androstenedione; 5-
diol: 5-androstene-3β,17β-diol; 5α-red: 5α-reductase; 17β-HSD: 17β-hydroxysteroid dehydrogenase; 
ADT:  androsterone; ADT-G: androsterone glucuronide ; DHEA: dehydroepiandrosterone ; DHEAS: 
dehydroepiandroserone sulfate ; DHT:  dihydrotestosterone; E1: estrone ; E1S:  estrone sulfate; E2:  
estradiol ; epi-ADT: epi-androsterone ; epi-ADTS: epi-androsterone sulfate; SULT1E1: estrogen 
sulfotransferase type 1; SULT1A3: phenol sulfotransferase type 3;  T: testosterone; UGT: UDT-
glucuronosyl transferase)  
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4.5 Leydig cell models in endocrine research 
Cell-based in vitro bioassays are used on a routine basis in basic and applied research. A transformed 
cell line is an immortalized population of cells originating from a specific tissue within an organism that, 
due to mutations, undergo continuous growth and division. Cell lines can therefore be grown for 
extended periods of time. The major challenge in  the development and maintenance of a cell line is to 
preserve the physiological phenotype (Rahman and Huhtaniemi, 2004). Leydig cell lines are often 
chosen in basic research to study testicular endocrine functions and to investigate the molecular basis 
for hormone actions, testicular cell interactions and tumor genesis. In applied research, Leydig cells 
are used as a model to study the mechanisms of endocrine disruptors. Fetal and adult Leydig cells 
differ markedly with respect to their physiology and morphology and have to be considered as two 
different cell types (Svechnikov et al., 2010). Until now, to the best of my knowledge, no fetal type 
Leydig cell line exists, though such a cell line could be of great interest to study the special features of 
fetal-type Leydig cells. Adult-type Leydig cells appear in the mouse testis at around postnatal day 10 
and increase markedly in number after postnatal day 15 (Saez, 1994).Primary Leydig cell cultures are 
the most physiological relevant cell model but are very difficult to culture, since these cells stop 
growing after the first trypinisation (Nagpal et al., 1994). 
Immortalized Leydig cell lines have been established by various methods such as spontaneous 
immortalization, like the TM3 cell line (Mather, 1980), primary cells transfected with viral oncogene 
(Nagpal et al., 1994), by hybridization of freshly isolated murine Leydig cells with existing immortalized 
Leydig tumor cells (Finaz et al., 1987) and from transgenic mouse Leydig cell tumors (Chalifour et al., 
1992). Ascoli and Puett generated the most frequently used Leydig cell line (MA-10) from a Leydig cell 
tumor originating from a C57BL/6 mouse (Ascoli, 1981; Ascoli and Puett, 1978). They generated the 
cells by first isolating them from a Leydig cell tumor (designated tumor M5480) and subsequently 
alternating their cultivation to and from in vitro and in vivo systems multiple times. Culture-derived 
tumors were cloned and clonal lines were isolated and characterized. Clones 10 and 12, later referred 
to as MA-10 and MA-12, respectively, were shown to have retained several functional characteristics 
of normal Leydig cells, such as gonadotropin binding, LH responsiveness and steroidogenic response 
(Ascoli, 1981; Ascoli and Puett, 1978; Lacroix et al., 1979). However, later studies claimed that 
steroidogenesis in MA-10 cells is impaired, since it would not proceed further than the formation of 
progesterone (Finaz et al., 1987). Another clonal Leydig cell line (mLTC1) derived from the same 
tumor M5480 was established and characterized by Rebois (Rebois, 1982). mLTC1 and MA-10/12 
seem to obtain very similar characteristics (Rebois, 1982). MA-10 cells are by far the most widely used 
Leydig cell line in steroidogenesis field. However, controversy surrounds this cell line, specifically 
concerning its ability to produce steroids. More recently a new Leydig cell line (BLTK1) was 
established from a tumor of a transgenic inhα/tag mouse (Kananen et al., 1996). BLTK-1 cells possess 
a large number of high-affinity LH receptors. They maintain their characteristics up to passage number 
45 (Kananen et al., 1996).  
Immortalized cell lines are limited as models, but as mentioned before, animal as well as human 
primary Leydig cells are expensive and difficult to culture. In addition, even suing sophisticated 
methods, it is difficult to isolate a pure Leydig cell fraction from animal testes (Lai et al., 2014). Also, 
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primary cells rapidly dedifferentiate upon cultivation and the duration of experiments is limited. Another 
major problem in studying steroidogenesis represents species dependent differences, therefore 
comparative analysis of hormone levels from different species should be taken with extreme caution. 
Furthermore, since the Leydig cells only form a small subpopulation of testicular tissue, a high number 
of animals are needed in order to carry out primary cell experiments, which raise ethical concerns and 
conflict with the 3R rules. Screening assays, requiring a high number of identically behaving cells 
would be complicated to perform. Another critical issue is the design of a stably transfected cell line. 
The establishment of stably transfected cell lines is only feasible in immortalized cells. 
4.6 Aims of the Leydig cell characterization project 
As described above, Leydig cell lines are very important tools for studying various aspects of 
steroidogenesis. However, caution must be taken when making conclusions using these models, since 
many enzymes involved in steroidogenesis are deregulated in cancer cells and importantly, Leydig cell 
lines derive from testicular cancers. Therefore, it is absolutely necessary to first characterize the cell 
lines to determine their suitability for planned assays. We have faced certain difficulties working with 
Leydig cell lines, such as the uncertainties about the predominant steroidogenic pathways or the 
abundance and formation of androgen metabolites. We therefore decided to characterize the mostly 
commonly used Leydig cell model, the MA-10 cells, and compare them with the newly generated 
BLTK-1 cell line. The validation of the testosterone production in the two cell lines was our focus, since 
a Leydig cell model with physiologically comparable basal testosterone production would be a 
significant improvement for endocrine research and help to facilitate our bioassay designs.  
A further goal was to validate existing methods of steroid measurements and to establish LC-MS/MS 
methods for the measurements of various endogenous steroids in cell media (supernatant). The 
quantification of steroids is challenging, since the results vary widely upon the method used (Rosner et 
al., 2007).  
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4.7 Paper Draft  
Comparison of androgen synthesis in MA-10 and BLTK-1 mouse Leydig 
cells 
4.7.1 Abstract  
Leydig cell lines are essential tools for the analysis of androgen production and for mechanistic studies 
of steroidogenesis. There is some discrepancy in the literature about the steroidogenic enzymes 
expressed in different cell lines and a careful analysis of steroidogenic pathways is crucial for the 
appropriate interpretation of the results. In the search for a suitable cell model to study the impact of 
xenobiotica on testosterone synthesis, we compared the widely used mouse MA-10 with the more 
recently established BLTK-1 cells. We found important differences between the two cell models. MA-
10 cells mainly produce testosterone via the well-known front-door pathway of 17β-HSD3-mediated 
reduction of androstenedione. In contrast, the BLTK-1 cell line produces only background levels of 
testosterone and predominately forms the inactive metabolite androsterone via 5α-reductase and 
subsequent 3α-HSD-induced metabolism of androstenedione. The differences may be explained by a 
higher expression of 17β-HSD3 and a lower expression of 3α-HSD1 in MA-10 compared with BLTK-1 
cells. Furthermore, we provide an explanation for the misinterpretation of some results in earlier 
studies because of difficulties in measuring steroids in complex matrices where multiple metabolites 
are present. Our results emphasize the limitations of both classical thin layer chromatography (TLC) 
and enzyme linked immunoassays (EIA) for the quantification of steroids in medium from cultured 
Leydig cells. We present a validated liquid chromatography-mass spectrometry (LC-MS)-based 
method for the reliable quantification of steroids and propose to recognize LC-MS as a gold standard 
in the assessment of androgen metabolites in studies with Leydig cells.  
4.7.2 Introduction 
It is important to characterize the mechanisms involved in androgen pathways in order to understand 
androgen disruption-related diseases such as cancer. Steroidogenic enzymes are potential targets for 
drugs, chemicals, natural products and environmental contaminants (Sanderson, 2006; Whitehead 
and Rice, 2006). Disrupted steroidogenesis may result in problems and diseases concerning 
reproductive development and fertility but may also play key roles in the development and progression 
of cancer. Certain types of cancer are directly related to AR activation by deregulated AR ligands such 
as testosterone or/and 5α-dihydrotestosterone.  
Leydig cells, which form a subpopulation of testicular cells, were identified in two distinct generations: 
fetal Leydig cell and adult Leydig cells (Svechnikov et al., 2010). Fetal and adult Leydig cells markedly 
differ in their morphological and biochemical properties. Adult Leydig cells are not even derived from 
preexisting fetal Leydig cells; it is hypothesized that they are derived from undifferentiated peritubular 
stem cells (Ge et al., 2006). However, fetal and adult Leydig cells share the principal function to 
produce androgens (Svechnikov et al., 2010). For research focusing on the male steroid axis, Leydig 
cell are the best model. Studies focusing on the molecular pathways of androgen formation are often 
performed in rodent models (Li et al., 2014; McNamara et al., 2012). For mechanistic studies, primary 
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testis cells are used from a very diverse range of animals (Mankidy et al., 2014; Morais et al., 2013). 
The use of animal studies pose ethical concerns and, in addition, there are significant differences 
between animal and human pathways (Furstenberger et al., 2012; Meyer et al., 2013). Furthermore, 
animal experiments generally do not significantly contribute to the elucidation of mechanisms 
(Andersen and Krewski, 2009; Holsapple et al., 2009). Primary human testis or prostate cells are 
generally not easy to obtain and culture conditions are difficult and expensive. Furthermore, since 
primary testis cells are difficult to keep in culture, they are not suited for screening assays requiring a 
multitude of conditions such as different time points or concentrations. 
There are only a limited number of different Leydig cell lines available and their characterization in the 
literature often is controversial. Ascoli in the 1980’s established a Leydig cell line from transplantable 
Leydig cell tumors (Ascoli, 1981). This cells line, the MA-10 cells, were shown to be gonadotropin 
receptor positive and able to produce  basal levels of pregnenolone, progesterone, 20α-progesterone, 
17α-hydroxyprogesterone, androstenedione and testosterone (Ascoli, 1981). However, it was later 
questioned whether the MA-10 cells express all of the key enzymes of steroidogenesis, especially with 
respect to production of testosterone (Midzak et al., 2011; Payne, 1990). In 2012, Forgacs et al. 
(Forgacs et al., 2012) introduced a new Leydig cell line, the BLTK-1, which was derived from cells that 
were isolated from a testicular tumor developed in a transgenic mouse expressing the mouse inhibin α 
promoter/ simian virus 40 T-antigen fusion gene (Rahman and Huhtaniemi, 2004). The BLTK-1 cell 
line was shown to produce progestines (Pregnenolone, 17α-hydroxypregnenolone, 17α-
hydroxyprogesterone) and to further metabolize them into androgens (dehydroepiandrosterone 
(DHEA), androstenedione, testosterone, DHT) and estrogens (estrone and 17β-estradiol) (Forgacs et 
al., 2012). Forgcas et al. based their conclusions on the mRNA expression and protein of steroidigenic 
enzymes and on steroidogenic end product measurement using EIA kits.  
In the present study, we compared MA-10 and BLTK-1 mouse Leydig cell lines regarding their intrinsic 
steroidogenic pathways. The results are of special interest regarding the testicular “back-door 
pathway”, a pathway first mentioned in 2000 (Shaw et al., 2000; Wilson et al., 2003) and leading to 
DHT formation by bypassing the intermediate testosterone. To our knowledge, this is the first study to 
compare androgen formation pathways for the quantification of androgens in different Leydig cell lines 
and to sub sequentially compare different methods for the quantification the androgens formed.  
4.7.3 Materials and Methods 
Cell culture of MA-10 and BLTK-1 cells 
The mouse Leydig cell line MA-10 (kindly provided by Professor Mario Ascoli, University of Iowa, Iowa 
City, IA (Ascoli, 1981)) was cultivated as described previously (Legeza et al., 2013). Briefly, cells were 
grown on 0.1% gelatin-coated cell culture dishes in DMEM/F12 medium (Invitrogen, Carlsbad, CA, 
USA) containing 20 mM HEPES (Gibco life technologies, Carlsbad, CA, USA), 15% horse serum 
(Gibco life technologies), and 50 µg/ml gentamicin (Sigma-Aldrich, St. Louis, MO, USA). The BLTK-1 
mouse Leydig cell line (kindly provided by Professor Huhtaniemi and Dr. Rahman, University of Turku, 
Turku, Finland (Forgacs et al., 2012)) was cultivated as described previously (Forgacs et al., 2012). 
Briefly, cells were maintained in DMEM/F12 medium (Invitrogen) with 10 % fetal bovine serum (Gibco 
life technologies) 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich). Both cell lines were 
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incubated under standard conditions (5% CO2, 37°C). For the LC-MS/MS samples, cells were 
cultivated in phenol red-free medium (Invitrogen). 
Determination of the mRNA levels of SDR5A1, HSD17B3 and HSD3A1 
Total RNA from MA-10 and BLTK-1 cells was extracted using Trizol reagent, followed by reverse 
transcription using the Superscript III reverse transcriptase (Invitrogen). The mRNA levels from 
different genes were analyzed using a Rotor-Gene 6000 light cycler (Corbett, Sydney, Australia). 
Briefly, reactions were performed in a total volume of 10 μl reaction buffer containing KAPA SYBR 
master mix (Kapasystems, Boston, MA, USA), 20 ng cDNA and specific oligonucleotide primers (Table 
4). Relative gene expression compared with the internal control glycerinaldehyde-3-phosphate-
dehydrogenase (GAPDH) was determined using the delta-delta-CT method. 
Gene Oligonucleotide primer forward Oligonucleotide primer reverse 
SDR5A1 5’-TCA-CCT-TTG-TCT-TGG-CCT-TC-3’ 5’-TTA-TCA-CCA-TGC-CCA-CTA-ACC-3’ 
HSD17B3 
5’-TGA-GTG-TGA-ATA-CAG-AGA-TAA-
AGG-3’ 
5’-TCC-GAT-CGT-GAC-ATA-TTT-CAA-
GG-3’ ‘ 
HSD3A1 
5’-GGT-TTT-TGG-GGC-AGA-GGA-TCA-3’ 5’-GGT-ACT-GGG-TGT-CAA-GAA-TGT-
CT-3’ 
Table 4: Oligonucleotide primers used for RT-PCR  
Determination of the androstenedione metabolizing rate by thin layer chromatography  
The activity of androstenedione consumption was measured using a modified protocol from Legeza et 
al. (Legeza et al., 2013). Briefly, cells were incubated in serum and steroid free DMEM/F12 medium 
containing 200 nM radiolabeled [1, 2, 6, 7-3H]-androstenedione (GE Healthcare, Little Chalfont, UK) for 30 
minutes (BLTK-1) and 4 hours (MA-10). The enzymatic reactions were terminated by adding unlabeled 
androstenedione and testosterone (Sigma-Aldrich) dissolved in methanol. The steroids were 
separated on UV-sensitive silica TLC plates (Macherey-Nagel, Oensingen, Switzerland) using a 
chloroform-methanol solvent system at a ratio of 9:1. Bands corresponding to the respective steroid 
were scraped off the TLC plate and transferred to tubes containing scintillation cocktail. Radioactive 
decay of androstenedione and corresponding metabolites were analyzed on a scintillation counter. 
Validation of the enzyme Immunoassay (EIA) kit for testosterone  
The EIA kit for testosterone (Cayman Chemical Company, Michigan, USA) was used according to the 
manufacturer’s instructions. 5α- and 5β-dihydrotestosterone, androstendiol, 5α-androstanedione, 
androsterone, eticholanolone and dihydroepiandrosterone were purchased from Steraloids (Newport, 
RI, USA). All tested metabolites were dissolved in ethanol, diluted in the buffer provided with the kit 
and measured at three different concentrations (150 pg/ml, 75 pg/ml and 37.5 pg/ml) in duplicate. 
Cross-reactivity was calculated in percentage of the recovery rate of the corresponding metabolite.  
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LC-MS/MS 
Sample preparation 
MA-10 and BLTK-1 cells at confluence of 80% and passage 5-10 were washed with phosphate 
buffered saline (PBS) and incubated with DMEM/F12 containing 200 nM of androstenedione for 4 
hours (MA-10 cells) or 30 min, 1 hour, 2 hours and 4 hours (BLTK.1 cells). Stock solutions were 
prepared in methanol for labeled internal standards (IS) (Steraloids) at a concentration of 10 mM. 
Thereafter, standards and deuterium labeled IS working solutions were prepared by mixing each 
individual stock solution to obtain a working concentration of 100 µM. Calibration curves were 
prepared by serial dilution of the working solutions of standards in DMEM/F12 phenol red-free medium 
in the range of 0.975 nM to 1000 nM. Cell supernatant was taken at the appropriate time point and IS 
at a final concentration of 0.1 µM in protein precipitation solution (zinc sulfate 0.8 M in water/methanol 
50/50 v/v) were added. After shaking vigorously for 10 min at 4°C, the samples were centrifuged 10 
min at 10’000 x g. Samples were transferred onto Oasis HBL SPE columns (Waters, Milford, MA, 
USA) that were preconditioned with methanol and water. Samples were washed 2 times with water, 
eluted with methanol and evaporated at a vacuum evaporator. Samples were reconstituted in 100 µl 
methanol and shacked vigorously for 30 min at 4°C.  
Separation, ionization and conditions for detection of androgens  
The samples were analysed by ultra-pressure liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS). An Agilent 1290 UPLC coupled to an Agilent 6490 triple quadruple mass 
spectrometer equipped with an electrospray ionization (ESI) source was used (Agilent Technologies, 
Basel, Switzerland). Analytes were separated by using a reversed-phase column (ACQUITY UPLC 
BEH C18, 1.7 µm, 2.1×150 mm, Waters, Wexford, Ireland) that was heated to 70ºC. Data acquisition 
and analysis was performed using Mass Hunter software (Agilent Technologies). The mobile phase 
consisted of water-acetonitrile-formic acid (A) (95/5/0.1; v/v/v) and (B) (5/95/0.1; v/v/v). The eluent 
gradients were set from 25 - 75% of B during 0- 20 min, and 100% of B at 22.min onwards. The run 
was stopped at 24 min, including washing and re-equilibration of the column. The flow rate was set to 
0.650 mL/min. Ionization was performed using an ESI source operated in the positive ion modes 
(Table 5). Fragmentation was tuned for each compound using Optimizer software (Agilent 
Technologies) except 5β-DHT and androstenediol were quantified using the precursor ion. Optimal 
conditions are shown in Table 5. The source parameters were set to gas temperature 290°C, gas flow 
14 L/min, nebulizer pressure 15 psi, sheath gas temperature 300ºC, sheath gas flow 11 L/min, 
capillary voltage 6000 V (positive), nozzle voltage 1500 V and cell accelerator voltage 4 V. Ion funnel 
parameters for positive and negative high pressure were set to 200 and 110 respectively. 
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Steroid RT  [min] 
Precursor 
Ion (m/z) 
Product 
ion (m/z) 
Collision 
energy (V) Polarity 
Internal 
Standard 
Androstenediol 7.4 255.2 255.2 0 Positive Testosterone-d2 
Androsterone 18.1 273.2 255.2 12 Positive Testosterone-d2 
Testosterone 8.1 289.2 97.1 28 Positive Testosterone-d2 
Androstenedione 9.5 287.2 97.1 20 Positive Testosterone-d2 
5α-DHT 12.5 291.2 159.1 24 Positive Testosterone-d2 
5ß-DHT 13.8 255.1 255.1 0 Positive Testosterone-d2 
Testosterone-d2 8.1 291.5 111.1 24 Positive  
Table 5: Overview of androgens measured and mass spectrometer properties 
4.7.4 Results 
Expression of steroidogenic enzymes (mRNA) in MA-10 and BLTK-1 cells 
The mRNA levels of three the key steroidogenic enzymes, 17β-HSD3, 3α-HSD1 and 5α-reductase1 
were measured using real-time polymerase chain reaction (RT-PCR) (Figure 10A and 10B). MA-10 
and BLTK-1 express HSD17B3 mRNA, encoding the key enzyme of the front-door pathway which 
catalyzes the activation of androstenedione to testosterone; however, the mean cycle threshold (ct) for 
HSD17B3 values of 28.2 in MA-10 cells and 31.1 in BTK-1 cells indicate a higher expression in MA-10 
cells. The 5α-reductase SRD5A1 mRNA encoding a key enzyme of the back-door pathway (Luu-The, 
2013) was highly expressed in both, BLTK-1 (ct value 18.8) and MA-10 cells (ct value 19.5). The 3α-
HSDs also are an enzyme family of with important roles in the back-door pathway, catalyzing the 
reaction from the androstanedione to the androsterone. HSD3A1, an important isoform of the 3α- 
HSDs, is expressed in both cell lines, with a much higher expression (ct value of 17.6) in BLTK-1 than 
in the MA-10 cells (ct value of 25.3).  
 A           B 
 
 
 
 
 
 
 
Figure 10: mRNA expression in MA-10 (A) and BLTK-1(B) Leydig cells differ. The expression of 
three key steroidogenic enzymes (SDR5A1, HSD3A1 and HSD17B3) and were measured in MA-10 
and BLTK-1 Leydig cells. The data represent the mean ± S.D. of three independent measurements.  
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Metabolism of androstenedione in MA-10 and BLTK-1 cells measured by using thin layer 
chromatography  
In a first step, we compared the ability of MA-10 and BLTK-1 cells to metabolize androstenedione by 
determination of the conversion rate of radiolabeled androstenedione (scintillation counting), following 
separation of the steroids by TLC. The BLTK-1 cells showed a much higher rate of androstenedione 
disappearance than MA-10 cells (Figure 11). After only 30 min of incubation 46% of the initially 
supplied androstenedione was converted to a product with similar migration behavior on the TLC plate 
than the unlabeled testosterone that was added to the reaction termination buffer. In contrast, only 
22% of the androstenedione supplied was converted by the MA-10 cells after 120 min. Thus, BLTK-1 
cells displayed a 5-10 times higher efficiency to metabolize androstenedione than MA-10 cells, despite 
clearly lower 17BHSD3 mRNA levels.  
 
Figure 11: Androstenedione degrad-
ation in the two different Leydig cell 
lines, MA-10 and BLTK-1. Scintillation 
counting following TLC was performed 
after incubation with 200 nM radiolabeled 
androstenedione (incubation time was 30 
min for the BLTK-1 cells and 2 hours for 
MA-10 cells). The data represent the mean 
± S.D. of three independent experiments. 
After adjusting the thin layer chromatography protocol (extended run, excision of several sections per 
lane) it could be shown, that the main metabolite formed in BLTK-1 migrates slightly slower than the 
testosterone control on the TLC plate. The unknown metabolite was formed rapidly, showing a reverse 
pattern compared with androstenedione disappearance (Figure 12). 
 
Figure 12: The rapid metabolism of 
androstenedione follows a reverse 
pattern to the formation of a new 
metabolite in adjusted TLC separation. 
Scintillation counting following adjusted 
TLC was performed after incubation with 
200 nM radiolabeled androstenedione at 
30 min, 1 hour, 2 hours and 4 hours. The 
data represent the mean ± S.D. of three 
independent experiments. 
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Assessment of the TLC results using LC-MS/MS 
In order to identify the metabolite predominately formed from androstenedione in BLTK-1 cells, we 
applied LC-MS/MS. Upon verification with an authentic standard we could show that not testosterone 
but androsterone is time-dependently formed from androstenedione in BLTK-1 cells (Figure 13). DHT 
and testosterone are produced in small quantities (less than 1% of total) in BLTK-1 cells. 
 
 
 
 
 
 
 
 
Figure 13: LC-MS/MS measurements show that androstenedione is time dependently 
metabolized to androsterone in BLTK-1 cells. The levels of androstenedione and androsterone 
were measured using LC-MS/MS after 30, 60 and 90 minutes. The data represent the mean ± S.D. of 
technical triplicates. 
Using LC-MS/MS measurements, we could show that MA-10 cells indeed produce testosterone 
following the incubation with androstenedione (Figure 14). DHT and androsterone were not produced 
at relevant levels. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Testosterone formation observed in LC-MS/MS measurements in MA-10: The level of 
testosterone in cell supernatant of MA-10 cells which incubated with 1000 nM androstenedione for 4h 
were measured using LC-MS/MS. The data represent the mean ± S.D. of technical triplicates. 
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Validation of the testosterone enzyme immunoassay kit 
Previous studies by Forgacs et al. (Forgacs et al., 2013; Forgacs et al., 2012) reported the production 
of testosterone by BLTK-1 cells based on the results from a testosterone EIA kit (Cayman Chemical 
Company, Michigan, USA). The validation of the kit by the provider did not include several androgen 
metabolites, including androstenediol. Therefore, we validated the EIA kit for cross-reactivity towards 
several androgen metabolites (Table 6 and Figure 15).The validation resulted in the detection of 
multiple metabolites from the front-door as well as the back-door pathway, confirming a high cross-
reactivity rate in this commercially available testosterone assay kit. 
mean recovery rate 
(cross-reactivity ) 
mean ± SD 
Testosterone 98.3 ± 9.6
5α-Androstanedione 20.6 ± 8.4
5α-Dihydrotestosterone 58.6 ± 8.8
5β-Dihydrotestosterone 28.5 ± 4.9
Androstenedione 25.4 ±6.2
Androstenediol 36.4 ± 2.8
Androsterone 16.4 ± 10.9
Dihydroepiandrosterone 5.5 ± 3.0
Etiocholanolone 18.3 ±0.6
 
Table 6: The EIA kit validated shows marked cross-reactivity. Different metabolites were tested in 
three concentrations (150 pg/ml, 75 pg/ml and 37.5 pg/ml) in duplicates. (The table shows the data in 
an alphabetical order) The data represent the mean values obtained within the three concentrations ± 
S.D.  
 
 
 
 
 
 
 
 
 
 
Figure 15: Graphical representation of cross-reactivity of metabolites obtained with the EIA kit 
validated. The different metabolites which were tested in three concentrations (150 pg/ml, 75 pg/ml 
and 37.5 pg/ml) in duplicates are shown in descending order. The data represent the mean values 
obtained within the three concentrations ± S.D. 
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4.7.5 Discussion 
The present study confirms the complexity of steroidogenesis and demonstrates the importance of the 
characterization of appropriate cell models for studying steroidogenesis for translational purposes. In 
addition, appropriate methods for detection and quantification are required. Our study compared two 
Leydig cell models and revealed marked differences in their predominant steroidogenic pathways. We 
focused on the well-established and broadly used mouse Leydig cell line MA-10 and the more recently 
established cell line BLTK-1 (Forgacs et al., 2012). The results indicate, that the MA-10 cell line 
follows the well characterized front-door pathway, where androstenedione is converted to testosterone 
by 17β-HSD3 as recently supported by Legeza et al. (Legeza et al., 2013). However, our results show 
that the time of incubation for testosterone formation from androstenedione is relatively long in MA-10 
cells, indicating a relatively modest expression of 17β-HSD3. Thus , the MA-10 cells partially lost the 
characteristics of primary Leydig cells, which have high expression of 17β-HSD3 (Luu-The, 2013). 
Although the mRNA expression of HSD17B3 and the conversion rates are relatively low, in 
contradiction to previous studies (Midzak et al., 2011; Rahman and Huhtaniemi, 2004), we 
demonstrate that MA-10 cells express functional 17β-HSD3 and produce testosterone from the 
inactive precursor androstenedione. Possible reasons for the discrepancy may include different 
passage numbers of the MA-10 cells used, culture conditions and/or different methods for detection 
and quantification that were applied in these studies.  
The 17β-HSD3–dependent conversion of androstenedione to testosterone is referred to as the “front-
door” pathway (Auchus, 2004), the common pathway by which testicular Leydig cells produces the AR 
ligand testosterone (Luu-The, 2013). However, under conditions of cellular stress such as in cancer, 
Leydig cells can undergo changes,  and as a consequence favor the formation of the more potent AR 
ligand DHT by bypassing testosterone formation, a process known as the “back-door” pathway 
(Auchus, 2004; Luu-The, 2013). Several back-door pathways have been identified so far. Their 
common feature is that they utilize intermediate metabolites, which were previously considered as 
decomposition products of steroidogenesis (Luu-The, 2013), for the production of potent androgens. 
Our results suggest that the Leydig cell model BLTK-1 favors the metabolism of androstenedione 
through a back-door pathway. Our results suggest that upon incubation with androstenedione, 5α-
steroid reductase1/2 (SDR5A1/2) catalyzes the formation of the intermediate 5α-androstanedione 
which is rapidly transformed to androsterone by 3α-HSD1/3. In the presence of both, 17β-HSD3 and 
5α-reductase1/2, androstenedione favors the binding of 5α-reductase1/2 (Luu-The, 2013; M. Samson, 
2010; Yamana, 2010). In tissues where high concentrations of testosterone are required, such as in 
the testis, SDD5A1 mRNA is approximately 85% lower than HSD17B3 mRNA (Luu-The, 2013). In 
tissue with 17β-HSD3 excess, testosterone is formed from androstenedione (Geissler et al., 1994). In 
BLTK-1 cells, the mRNA expression of SDR5A1 is much higher than the mRNA levels of HSD17B3. 
This finding is coherent with our observations that testosterone formation is limited to less than 1% of 
the total conversion products identified by LC-MS/MS. Surprisingly, SDR5A1 mRNA is also highly 
expressed in MA-10 cells. However, LC-MS/MS and TLC measurements suggest that testosterone is 
the major metabolite in the MA-10 cell line. Further experiments are required to understand the 
reasons why MA-10 cells still favor the conversion of androstenedione to testosterone. The protein 
expression and the functionality of MA-10 5α-reductase1/2 have to be examined. The absence of the 
Project 2: Androgen metabolism in Leydig cells 
59 
conversion of androstenedione to 5α-androstanedione may be due to the absence of cofactors or low 
protein expression. 5α-androstanedione in BLTK-1 cells is rapidly transformed into androsterone. 
Androsterone is thought to be an inactive steroid that is found in the circulation at relatively high 
concentrations (around 1400 nM) in healthy men (Luu-The, 2013). It was reported by Labrie et al. that 
androsterone is the most abundant inactive precursor steroid in males aged of 20- 30 years (Labrie et 
al., 1997a). Besides the formation of androsterone, very low amounts of DHT are formed in BLTK1- 
cells. The reasons why MA-10 cells predominately favor the front-door pathway whereas in BLTK-1 
cells favor the back-door pathway remains unexplained so far. Both cell lines originate from cancer 
cells, though they were isolated using different methodologies (Rahman and Huhtaniemi, 2004).  
Measurements of complex steroid matrices by simple laboratory techniques such as TLC are very 
difficult and prone to error. We propose that two dimensional TLC systems should be used for 
validated applications only and mass spectrometry based methods should be recognized as gold-
standard. The immunoassay kit that was used in earlier studies (Forgacs et al., 2013; Forgacs et al., 
2012) showed high cross-reactivity towards metabolites of the back-door pathway that have not all 
been included in the validation by the provider. Despite ability of the kit to accurately determine 
testosterone levels within a controlled sample, unfortunately, it also detected a wide variety of other 
androgen metabolites. This led to misinterpretation and overestimation of the testosterone levels in 
earlier studies (Forgacs et al., 2013; Forgacs et al., 2012). Testosterone-selective antibodies are very 
difficult to design, due to structural similarities to other metabolites of the androgen axis. The 
interpretation of the results of the recent study by Forgas et al (Forgacs et al., 2013) need to be 
revisited. The data presented as testosterone concentrations may represent androsterone levels or a 
mixture of metabolites of the back-door pathway. Forgas et al. tested the impact of triazine herbicides 
on steroidogenesis. They proposed that in the cell supernatant of BLTK-1 cells incubated with several 
triazide herbicides testosterone may be up regulated, which may reflect androsterone instead. They 
also conducted experiments on the mRNA levels of several enzymes involved in steroidogenesis and 
showed that they are altered at high micromolar concentrations of the herbicides. Importantly, a direct 
link between the elevation of “testosterone” levels and the up regulation of 17β-HSD3 could not be 
concluded from their study, which is in line with our assumption that the elevated steroid may not be 
testosterone but rather androsterone. Herbicides were shown to induce the steroidogenic acute 
regulatory protein (StAR), which exerts its action on the entire steroidogenic pathway. This suggests 
that triazine herbicides may act as general disruptor of steroidogenesis and not via the induction of 
17β-HSD3- mediated testosterone production.  
In conclusion, the Leydig cell lines MA-10 and BLTK-1 both express key elements involved in 
steroidogenesis, yet their enzymatic profiles differ. Both models are equally suitable to study 
regulatory effects on the HSD17B3 mRNA level since both cell lines possess functional 17β-HSD3. 
However, the lack of a selective antibody for 17β-HSD3 limits studies on the protein level. With 
respect to enzymatic activity assays, MA-10 cells and BLTK-1 cells differ markedly. For studies 
measuring the enzymatic activity of 17β-HSD3, MA-10 cells should be chosen, since upon incubation 
with androstenedione the preferred pathway is the 17β-HSD3-mediated reduction to testosterone. Our 
data suggest that BLTK-1 cells represent a good model to study effects on the back-door or 
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degradation pathways, since androstenedione is predominately metabolized to the inactive androgen 
androsterone. For future studies, the regulation of the key enzymes determining the back-door 
pathways in BLTK-1 cells, specifically 5α-reductase1/2 should be investigated in more detail. Such 
studies may unveil the mechanism by which 5α-reductase inhibitors induced 5α-reductase resistance 
in castration resistant prostate cancer 
.
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5. Project 3: Transcriptional regulation of 17β-hydroxysteroid 
dehydrogenase 
5.1 Introduction 
The importance of a fully functional 17β-HSD3 is, as described in chapters above, essential for sexual 
differentiation and development as well as for multiple health aspects. It is generally accepted that 
reduced enzyme expression/function or events that results in enzymatic dysregulation, underlie the 
pathogenesis of multiple disorders. This chapter focuses on different aspects of 17β-HSD3 up 
regulation, including promoter activation, mRNA levels and enzymatic activity.  
5.1.1 Possible consequences of 17β-hydroxysteroid dehydrogenase type 3 up regulation  
17β-HSD3 up regulation directly results in higher testosterone levels. Dysregulated testosterone levels 
are associated with cancer progression, although its distinct mechanistic role remains unclear and 
needs further research. Older studies showed a direct association between testosterone levels and the 
development of various types of cancer, in addition to an increased risk of overall mortality (Gann et 
al., 1996; Parsons et al., 2005). More recently, there is increasing evidence that higher testosterone 
levels do not directly contribute to the onset of cancer (Eisenberg et al., 2014; Orsted et al., 2014). It 
was concluded by Orsted et al. (Orsted et al., 2014) that increased plasma testosterone levels are 
associated with an 80% higher risk of early death following cancer diagnosis in both men and women, 
but do not alter the risk of developing cancer in the first place. It appears that high testosterone levels 
negatively influence the pathogenesis of cancer and therefore the pathophysiological mechanisms of 
testosterone need to be further evaluated. It was shown in two older studies, that testosterone 
stimulates the growth of lung and colon cancer cells in vitro and that this effect can be halted with anti-
androgens (Maasberg et al., 1989; Tutton and Barkla, 1982). In a recent review, focusing on molecular 
pathways of prostate cancer (Mazaris and Tsiotras, 2013), several mutations in various genes 
encoding for enzymes of the steroidogenesis such as in HSD3B1/2 (Chang et al., 2002) or in CYP17 
allele (Hughes et al., 2005) were identified and are suspected to contribute to prostate cancer. The 
AR, the target nuclear receptor of testosterone, is widely accepted to play an important role in the 
initiation and growth of prostate cancer (PC) (Taplin and Balk, 2004).  
PC is typically treated in the clinic with androgen deprivation therapy. Within the different stages and 
etiology of PC, different drug regimens are selected. Predominately in the early phases of the disease, 
inhibitors of steroidogenesis such as 5α-reductase inhibitors (e.g. finasteride or dutasteride) or the 
CYP17-inhibitors (e.g abiraterone) are administered (Fryczkowski et al., 2014). Such enzyme 
inhibitory treatment results in castration-like low androgen levels. In locally advanced as well as in 
metastatic PC, AR inhibitors are used to induce chemical castration (Poutiainen et al., 2014). About 
85% of PCs (in terms of low prostate specific antigen (PSA), the clinical biomarker of prostate cancer) 
can be successfully treated (Taplin and Balk, 2004). However, there are a distinct set of PCs which 
develop resistance towards androgen deprivation therapy. This type of PC is referred to as hormone-
independent PC. The AR is believed to play an important role in the shift from an androgen-dependent 
to androgen-independent cancer (Taplin and Balk, 2004). Furthermore, the facts that a majority of PCs 
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express high levels of AR and are dependent on testosterone for growth, underlie the importance of 
this receptor-ligand interaction for the development of PC (Cai and Balk, 2011). In addition to PC, AR 
activation plays an important role in the development of breast cancer. However, unlike in PC, AR 
expression and activation plays a more complex role in breast cancer growth and development, since 
beneficial effects have been demonstrated with both androgens and anti-androgen therapy, 
suggesting that multiple factors are involved (D'Abreo and Hindenburg, 2013). In summary, the role of 
testosterone in the development, progression and outcome of cancer remain to be fully understood. 
However, it is assumed that dysregulation of the processes that control testosterone action, either 
enzymatic or via target receptor activation, contribute to cancer development. 
5.1.2 Inflammation, tumor necrosis factor-α and cancer 
Tumor necrosis factor-α (TNF-α) was initially identified as “endotoxin-induced serum factor that causes 
necrosis of tumors” (Carswell et al., 1975). Extensive research has been carried out on the effects of 
TNF-α, including cell cycle, cell death and survival (Locksley et al., 2001). There was initial 
enthusiasm that TNF-α could be used as an anticancer cytokine. However, this faded when it was 
shown that TNF-α and its down-stream targets are in fact major mediators of cancer-related 
inflammation (Balkwill, 2009; Pikarsky et al., 2004; Sethi et al., 2008). Besides its roles in cancer, TNF-
α was identified as a master regulator of inflammation, resulting in TNF-α antagonists being developed 
to treat rheumatoid arthritis and other inflammatory diseases (Feldmann, 2002; Sands et al., 2004; 
Tracey et al., 2008). Pro-tumor actions of TNF-α are mainly mediated via the tumor necrosis factor 
receptor 1 (TNFR1) (Harrison et al., 2007). Tnfr1-/- mice show attenuated development of primary 
cancers and metastases compared to wild-type mice (Arnott et al., 2004; Popivanova et al., 2008). 
The link between TNF-α, inflammation and cancer is well established, however, it is still debated 
whether TNF-α is a therapeutic target, a treatment or both. Efforts still persist to use the TNF-α tumor-
destructive activity as therapy (Daniel and Wilson, 2008). 
 
TNF-α exerts its action via multiple pathways, which are still being investigated. However, the most 
commonly known and best characterized pathway of TNF-α action is the activation of nuclear factor 
'kappa-light-chain-enhancer' of activated B-cells (NF-κB). Briefly, TNF-α activates the cytoplasmic 
protein I kappa B-Kinase (IKK), which phosphorylates the inhibitory I kappa Bα-protein (Mercurio et al., 
1997). This phosphorylation results in the dissociation of IκBα from NF-κB, which then translocates 
into the nucleus and activates the expression of target genes. NF-κB interacts with the glucocorticoid 
receptor (GR), such that GR activation antagonizes NF-κB induction (Rao et al., 2011).  
Another known TNF-α signalling pathway is mediated through the mitogen activated protein kinases 
(MAPKs) (Sabio and Davis, 2014). TNF-α-dependent receptor activation ultimately results in a 
transcriptional up regulation through a cascade starting with the activation of MAPK kinase kinase 
(MAP3K) which phosphorylates MAPK kinase (MAP2K) which in turn phosphorylates MAPK, which 
finally activates downstream transcription factors, such as AP-1 or ATF-2 (Sabio and Davis, 2014). 
Three MAPK cascades have been defined: ERK (extracellular signal-regulated kinase), JNK (c-Jun N-
terminal kinase) and p38 MAPK (Sabio and Davis, 2014).  
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Li et al. identified the p38 MAPK pathway (Li et al., 2005). This pathway involves the recruitment of 
receptor interacting protein (RIP) by TNFR-associated death domain (TRADD). RIP recruits MAP3K 
which in turn phosphorylates the MAPK kinase 3 and 6 (MAPKK3 and MAPKK 6 ), which leads to p38 
MAPK activation (Aggarwal, 2003). The JNK MAPK pathway involves recruitment of the MAPK 
kinases 4 and 7 (MKK4 and MKK7); the ERK MAPK pathway is mediated by MAPK kinases 1, 2 and 5 
(MKK1/2 and MKK5) (Sabio and Davis, 2014). Figure 16 provides an overview on the major signalling 
pathways of TNF-α, NF-κB and the three major MAPK pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Overview of the main TNF-α signalling pathways. 
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5.2 Our approach: Study the transcriptional regulation of 17β-
hydroxysteroid dehydrogenase 3 
Steroidogenesis and steroidogenic effects can be studied at different levels. Since most research 
groups focus on nuclear receptors, we decided to focus on the enzymes responsible for the 
interconversion of active and inactive hormones. In our studies, we addressed the dysregulation of 
17β-HSD3, the key enzyme converting androstenedione to testosterone in the testis in Leydig cells. 
We believe that dysregulation of 17β-HSD3 is an important contributor to the pathologies discussed 
above. By stably transfecting the MA-10 mouse Leydig tumor cells with a 2.8 kb sequence containing 
the putative human HSD17B3 promoter and a downstream luciferase reporter, we created a tool to 
screen for androgen disruption. This approach, to the best of my knowledge, is a novel tool for 
studying steroidogenesis.  
5.3 Focus part A: The inflammatory cytokine TNF-α activates the 
promoter of 17β-hydroxysteroid dehydrogenase 3 
Within the course of our studies, we observed that the inflammatory cytokine TNF-α activates the 
HSD17B3 promoter. Inflammatory processes mediated by TNF-α are strongly associated with cancer 
development and progression (Balkwill, 2009). Taken together, we hypothesize that HSD17B3 
promoter dysregulation could have an impact on inflammation mediated carcinogenesis, e.g. tumors 
which chronically secrete TNF-α could contribute to higher testosterone levels due to increased 17β-
HSD3 activity, which would in turn promote the growth of androgen sensitive tumors.  
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5.4 Part A manuscript draft:  
TNF-α stimulates testosterone production by p38 MAPK-
dependent activation of 17β-hydroxysteroid dehydrogenase 3 
promoter 
5.4.1 Abstract 
Androgens play a key role in physiological and pathophysiological processes. They play a critical role 
in male sexual development as well as in growth and progression of testicular and prostate cancer In 
the testis the reduction of the weak androgen ∆4-androstene-3, 17-dione (androstenedione) to the 
potent androgen testosterone is catalysed by the short-chain dehydrogenase/reductase 17β-
hydroxysteroid dehydrogenase type 3 (17β-HSD3). Thus, impaired regulation of testosterone 
production by this enzyme is likely to contribute to androgen-dependent diseases. A risk factor closely 
linked with cancer is inflammation. The pro-inflammatory cytokine TNF-α plays important roles in the 
pathogenesis of chronic inflammatory diseases and cancer. Cancer-related inflammation reflects a 
state where cells and mediators of inflammation, such as TNF-α, form an important part of the tumor 
microenvironment. Such conditions may promote the pathogenesis of cancer and lead to further 
growth of the tumor. In the present study, we characterized the effects of the inflammatory cytokine 
TNF-α on the regulation and expression of 17β-HSD3. Performing transactivation assays in MA-10 
mouse Leydig cells stably expressing a luciferase reporter under the control of the HSD17B3 
promoter, we observed an activation of the reporter gene expression upon incubation with TNF-α. The 
results were confirmed in BLTK-1 mouse Leydig cells transiently transfected with the reporter 
construct. To confirm the results obtained from the reporter gene assays, we measured HSD17B3 
mRNA levels by real-time RT-PCR. Furthermore, we showed that TNF-α induced 17β-HSD3 enzyme 
activity. We suggest that TNF-induced 17BHSD3 promoter activation and the subsequently enhanced 
testosterone production plays an important role within the interaction of inflammation, elevated 
testosterone concentrations and cancer pathogenesis. 
5.4.2 Introduction 
17β-HSD3 is a key steroidogenic enzyme in humans and animals. It converts the inactive precursor 
steroid androstenedione to the potent androgen receptor (AR) ligand testosterone. Dysregulated 
testosterone levels have been associated with cancer. Previous studies showed a direct association 
between testosterone levels and the development of various types of cancer as well as an increased 
risk of overall mortality (Gann et al., 1996; Parsons et al., 2005). It was shown in two older studies, 
that testosterone stimulates the growth of lung and colon cancer cells in vitro and that this effect can 
be halted with anti-androgens (Maasberg et al., 1989; Tutton and Barkla, 1982). However, there is 
increasing evidence that higher testosterone levels do not directly contribute to the development of 
cancer (Eisenberg et al., 2014; Orsted et al., 2014) but that increased plasma testosterone levels are 
associated with an up to 80% higher risk of early death following cancer diagnosis in both men and 
women. It appears that high testosterone levels negatively influence the pathogenesis of cancer. Such 
pathophysiological mechanisms involving testosterone need to be further validated. However, it has 
been observed that a majority of prostate tumors express high levels of the testosterone target 
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receptor, the AR and that increased expression of AR in cancer cells is dependent on testosterone 
(Cai and Balk, 2011). These observations emphasize the importance of both testosterone and the AR 
in PC. In summary, elevated testosterone levels are assumed to play a role in the development, 
progression and outcome of cancer. However, the role of testosterone in cancer has yet to be fully 
understood. 
The link between cancer and inflammation has been clearly established and is well accepted. 
Controlled inflammation is essential for the survival of an organism. However, when inflammation is 
unresolved it leads to enhanced formation of reactive oxygen species that might contribute to many 
acute and chronic pathologies including cancer (Balkwill and Mantovani, 2001; Coussens and Werb, 
2001). Cytokines mediate a broad range of processes involved in the pathogenesis of cancer 
(Candido and Hagemann, 2013). The prototype among the proinflammatory cytokines is the tumor 
necrosis factor alpha (TNF-α). Its critical role in chronic inflammatory states is well known (Feldmann 
and Maini, 2008). As its name suggests TNF-α was initially shown to be toxic for tumor cells at high 
concentrations (Carswell et al., 1975). However, the tumor promoting function of TNF-α has been 
clearly demonstrated in mice (Moore et al., 1999). Cancer, in both men and women, is the second 
most common cause of death (after cardiovascular diseases) in economically developed countries and 
the leading cause of death in developing countries (Jemal et al., 2011). In males, prostate cancer is 
the cancer type with the highest incidence (Siegel et al., 2014), about 1-2 men in every 10 are affected 
(lifetime prevalence) (Siegel et al., 2014). Approximately 85% of all PCs can be successfully (in terms 
of low prostate specific antigen (PSA), the clinical biomarker prostate cancer) treated with inhibitors of 
steroidogenesis, such as; 5α-reductase inhibitors, CYP17-inhibitors or AR antagonists (Fryczkowski et 
al., 2014; Poutiainen et al., 2014). However, there are distinct forms of PC, which develop resistance 
towards androgen deprivation therapy during their progression. This type of PC is referred to as 
hormone-resistant PC. The AR is suggested to play an important role in this shift from androgen-
dependent to androgen-independent cancer (Taplin and Balk, 2004).  
To study the promoter regulation of HSD17B3, we designed a novel tool. Mouse Leydig cells (MA-10 
cells) derived from a Leydig cell tumor stably expressing a luciferase reporter gene under the control 
of a 2.8 kb sequence of the human HSD17B3 promoter. This cell line can be used in screening assays 
to identify potential disrupters of the testosterone formation. Furthermore, this tool may help to identify 
upstream factors (such as transcription factors or nuclear receptors) involved in the HSD17B3 
promoter regulation. 
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5.4.3 Materials and Methods 
Cultivation of MA-10 and BLTK1 cells 
The mouse Leydig cell line MA-10 (kindly provided by Professor Mario Ascoli, University of Iowa, Iowa 
City, IA (Ascoli, 1981)) was cultivated as described previously (Legeza et al., 2013). Briefly, cells were 
grown on 0.1% gelatin-coated cell culture dishes in in DMEM/F12 medium (Invitrogen, Carlsbad, CA, 
USA) containing 20 mM HEPES (Gibco life technologies, Carlsbad, CA, USA ), 15% horse serum 
(Gibco life technologies, Carlsbad, CA, USA )), and 50 µg/ml gentamicin (Sigma-Aldrich, St. Louis, 
MO, USA). The BLTK-1 mouse Leydig cell line (kindly provided by Professor Huhtaniemi and Dr. 
Rahman, University of Turku, Turku, Finland (Forgacs et al., 2012)) was cultivated as described 
previously (Forgacs et al., 2012). In brief, cells were maintained in DMEM/F12 medium (Invitrogen) 
containing 10% fetal bovine serum (Sigma-Aldrich) 100 U/ml penicillin and 100 μg/ml streptomycin 
(Sigma-Aldrich). Both cell lines were incubated under standard conditions (5% CO2, at 37°C).  
Generation of a reporter luciferase construct under the control of a 2.8 kb upstream sequence 
of the human HSD17B3 gene 
Primers to amplify the 2,800 base pairs (bp) upstream region of the HSD17B3 promoter were 
designed using the Primer-BLAST program and synthesized by Microsynth AG (Balgach, Switzerland). 
The sequences of the primers are listed in Table 7. 
 
2.8kb promoter HSD17B3 oligonucleotide 
primer forward 
2.8kb promoter HSD17B3 oligonucleotide 
primer reverse 
5’-GGT-ACC-GCA-GCA-ATA-CAC-AGA-
GGT-AAA-TTG-AG-3’ 
5’-GCT-AGA-ATG-CCT-CCT-GGG-ACC-
ACG-CTG-CTC-T-3’ 
Table 7: Oligonucleotide primers used for the amplification of the 2.8kb sequence of the 
HSD17B3 promoter  
 
The sequence in the putative promoter region of the human HSD17B3 was amplified with PCR under 
standard conditions using human genomic DNA as a template. The PCR product was loaded onto a 
1.5% agarose gel. The amplicon was excised from the gel and purified using the Wizard SV Gel and 
PCR Clean-Up System (Promega. Madison, WI, USA). For convenient cloning in an intermediate 
vector, TA cloning was performed using the pGEM-T Easy vector (Promega). For this purpose, a 
stretch of poly-A nucleotides was added to the purified product by TaqPolymerase (Invitrogen). 
Subsequently, the product was purified again and ligated into the pGEM-T Easy vector (Promega). For 
all ligations the following formula was used to calculate the amount of insert and vector in the ligation 
reaction: (50 ng vector x kb insert/kb vector) whereas the ratio kb insert:kb vector was 3:1. The ligation 
product was transformed into competent E.coli cells of the DH5a strain. Several colonies were picked 
and plasmid DNA was isolated using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich). The plasmid 
DNA was then digested with the restriction enzymes KpnI (recognition site 5’ GGTACC) and NheI 
(recognition site 5’ GCTAGC), (New England Biolabs, Ipswich, MA, USA). Recognition sequences for 
these sites were included at the 5’ends of the forward and reverse primer, respectively. Colonies 
positive for the pGEM-T easy vector containing the insert were selected and sequence verified. For 
ligation to the pGL4.17 vector, the insert was digested from the pGEM-T easy vector with the KpnI and 
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NheI restriction enzymes. The vector was subjected to the same digestions and was additionally 
dephosphorylated using alkaline phosphatase (Roche, Basel, Switzerland) to prevent linearized 
plasmid from self-ligating. The ligation of the vector with the insert was performed using the T4 ligase 
(Promega). The ligation reaction was transformed into competent bacteria and several colonies were 
tested for the presence of the vector containing the insert.  
Generation of MA-10 cells stably expressing the HSD17B3 promoter-luciferase reporter 
MA-10 cells (kindly obtained from Professor Mario Ascoli, University of Iowa, Iowa City, IA (Ascoli, 
1981)) at passage 5 were transfected using Lipofectamine 2000 transfection reagent (Invitrogen, 
Carlsbad, CA) with the HSD17B3 promoter-luciferase plasmid (described above) containing a 
neomycin resistance gene. Transfected cells were screened upon exposure to 200 µg/ml G418 
(Invitrogen) over two weeks. Single clones stably expressing the plasmid were selected from 
neomycin resistant MA-10 cells. Isolated single clones were verified for their luciferase activity in 
transactivation assays measuring the light signal from luciferin production at 470 nm on a Spectramax 
L (Molecular Devices, Sunnyvale, CA, USA). Cell clones expressing medium to high levels of 
luciferase were further sub-cultivated for two weeks with DMEM/F12 medium containing 200 µg/ml 
G418 to maintain selective pressure. The single clone designated as MA-10C2 was used for our 
experiments.  
HSD17B3 promoter transactivation assays  
MA-10C2 cells were seeded on 24-well plates at a confluence of 60%. The following day, they were 
incubated with TNF-α (Sigma-Aldrich) at a concentration of 10 ng/µl, dexamethasone (Sigma-Aldrich) 
at a concentration of 100 nM or SB202/190 (Sigma-Aldrich) at concentration of 20 µM for 24 hours at 
standard conditions ( 37°C, 5% CO2). After incubation, cells were washed with phosphate buffered 
saline (PBS), lysed with Tropix lysis buffer (Applied Biosystems, Foster City, CA) supplemented with 
0.5 mM dithiothreitol, and frozen at -80°C following a 10 minutes incubation at room temperature. 
Lysates were analyzed for luciferase activity using a luciferine-solution (Rebuffat et al., 2004) at 470 
nm on a Spectramax L (Molecular Devices). Levels were normalized to DMSO control treatments.  
Measurements of HSD17B3 mRNA with RT-PCR 
BLTK-1 cells were used in our assays between passages 10-15. BLTK-1 cells were seeded in 6 well 
plates at 60% confluence in DMEM/F12 for 12 h. Cells were washed once with PBS and incubated for 
24 h in culture medium containing TNF-α (Sigma-Aldrich) at a concentration of 10 ng/µl, 
dexamethasone (Sigma-Aldrich) at a concentration of 100 nM or SB202/190 (Sigma-Aldrich) at 
concentration of 20 µM (or combined treatments) for 24 hours at standard conditions (37°C, 5% CO2). 
DMSO at a concentration of 0.01% was used as solvent control. Total mRNA was extracted using the 
Trizol method (Invitrogen). Total mRNA (2 µg) was reverse transcribed into cDNA using the 
Superscript-III First-Strand Synthesis System and oligo-dTs (Invitrogen). Relative quantification of 
mRNA expression levels was performed by RT-PCR on a RotorGene 6000 (Corbett, Sydney, 
Australia) using the KAPA SYBR FAST qPCR Kit (Kapasystems, Boston, MA, USA) with specific 
oligonucleotide primers for Hsd17B3 (forward primer: 5’-TGAGTGTGAATACAGAGATAAAGG-3’; 
reverse primer: 5’-TCCGATCGTGACATATTTCAAGG-3’). Relative gene expression was normalized 
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to the internal control gene glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH) using the delta-
delta-CT method. 
17β-hydroxysteroid dehydrogenase activity assay 
The enzymatic activity of 17β-HSD3 was measured using a modified protocol from Legeza et al. 
(Legeza et al., 2013). Briefly, 12 hours following the seeding of MA-10 cells at 60% confluence in 96 
well plates, cells were washed once with PBS and incubated in DMEM/F12 medium containing either 
TNF-α at a concentration of 10 ng/ul or DMSO as solvent control (0.01 %) and incubated at standard 
conditions for 24 h (37°C, 5% CO2). Cells were then washed once with PBS and incubated in steroid 
free DMEM/F12 medium containing 200 nM radiolabeled [1, 2, 6, 7-3H]-androstenedione (GE Healthcare, 
Little Chalfont, UK) for 4 hours. Cells treated with the 17β-HSD3 inhibitor benzophenone-1 (BP-1) 
(Sigma-Aldrich) were pre-treated with 10 µM BP1 for 20 min allowing BP1 to enter the cells and to 
access 17β-HSD3 prior to addition of androstenedione. The enzymatic reactions were terminated by 
the addition of unlabeled androstenedione and testosterone dissolved in methanol. The steroids were 
separated on UV-sensitive silica TLC plates (Macherey-Nagel, Oensingen, Switzerland) using a 
chloroform-methanol solvent system at a ratio of 9:1. Bands corresponding to the respective steroid 
were scraped off the TLC plate and transferred to tubes containing scintillation cocktail. Radioactive 
decay of androstenedione and corresponding metabolites were analyzed on a scintillation counter. 
Promoter analysis by TFSearch 
The 2.8 kilo base sequence of the putative promoter of HSD17B3 was analyzed using the in silico tool 
TF search (http://www.cbrc.jp/research/db/TFSEARCH.html) programmed by Y. Akiyama, Kyoto 
University, Japan. Threshold score for matches was set at 85%.  
Statistical analysis 
Data are expressed as the mean ± standard deviation (S.D.) of at least three independent 
experiments. The significance of differences within the data was assessed by one-way analysis of 
variance (ANOVA), with Tukey post-test for multiple comparisons.  
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5.4.4 Results 
Activation of 17β-hydroxysteroid dehydrogenase type 3 promoter by TNF-α in MA-10 cells  
In order to test our hypothesis that TNF-α can induce HSD17B3 promoter activity, we treated MA-
10C2 cells for 24 h with TNF-α. We observed an 8-fold up regulation in promoter activity (Figure 17). 
To determine the pathway by which TNF-α exerts its action, we treated the cells with a selective p38 
mitogen activated protein kinase-(MAPK) inhibitor (SB202/190) and the GR agonist dexamethasone. 
Dexamethasone was not able to reverse the effect of TNF-α on the HSD17B3 promoter. In contrast, 
SB202/190 was able to suppress the TNF-mediated HSD17B3 promoter activation, indicating the 
involvement of p38 MAPK.  
 
 
 
 
 
 
 
 
 
Figure 17: TNF-α potently activates the HSD17B3 promoter through p83 MAPK. MA-10C2 cells 
stably expressing a luciferase reporter gene under the control of the human HSD17B3 promoter (clone 
MA-10C2) were treated with 10 ng/ µl TNF-α. A significant activation of the HSD17B3 promoter could 
be observed. Simultaneously treatment with dexamethasone at 100 nM was not able to reverse the 
effects of TNF-α. Upon co-incubation with TNF-α and 20 µM of the selective p38 MAPK inhibitor SB 
202/190, the activation of the promoter was suppressed. The data represent the mean ± S.D. of three 
independent experiments performed in triplicate. ***p ≤ 0.001. 
In order to confirm these effects in a second cell line, the expression plasmid for the luciferase reporter 
under the control of the human HSD17B3 promoter was transiently transfected into mouse BLTK-1 
Leydig cells. Similar to the results above, TNF-α induced HSD17B3 expression (data not shown).  
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Elevated 17β-hydroxysteroid dehydrogenase type 3 enzyme activity upon treatment of MA-10 
cells with TNF-α  
In order to confirm that increased HSD17B3 promoter activity translated to an increase in the 
conversion of androstenedione to testosterone, we measured the enzymatic activity of 17β-HSD3 in 
MA-10 cells. We observed a two-fold increased 17β-HSD3 activity following TNF-α treatment. Upon 
inhibition of 17β-HSD3 with benzophenone-1 (BP1), a chemical UV-filter shown to inhibit 17β-HSD3 
(Nashev et al., 2010), the effect could be blocked (Figure 18).  
 
 
 
Figure 18: 17β-HSD3 enzyme activity is significantly 
increased in MA-10 cells upon treatment with  
TNF-α. MA-10 cells treated with 10 ng/µl of TNF-α 
showed enhanced 17β-HSD3 enzyme activity. Upon 
co-incubation with TNF-α and BP-1, a 17β-HSD3 
inhibitor, the conversion from androstenedione to 
testosterone was inhibited. The data represent the 
mean ± S.D. of three independent experiments 
performed in triplicates. *p ≤ 0.05,***p ≤ 0.001. 
 
17β-hydroxysteroid dehydrogenase type 3 mRNA levels are elevated in TNF-α treated  
BLTK-1 cells  
In order to confirm that the increased 17β-HSD3 activity upon treatment with TNF-α resulted in 
enhanced transcription of the endogenous HSD17B3 gene we measured the mRNA level in BLTK-1 
mouse Leydig cells, following treatment with TNF-α. In correlation with the promoter activity, we 
observed an 8 fold increase in HSD17B3 mRNA levels which could by suppressed by co-treatment 
with SB202/190 (Figure 19). 
 
 
 
Figure 19: HSD17B3: mRNA levels of are markedly 
elevated in TNF-α treated BLTK-1 cells. BLTK-1 cells 
treated with 10 ng/µl TNF-α showed elevated HSD17B3 
mRNA levels. Upon co-incubation of TNF-α and 20 µM 
SB 202/190, the mRNA up regulation was reversed. 
The data represent the mean ± S.D. of three 
independent experiments performed in triplicates.  
***p ≤ 0.001. 
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Promoter analysis for potential transcription factor binding sites 
The 2.8 kb HSD17B3 promoter sequence was analyzed for the identification of potential transcription 
factor binding sites using the TFSearch software (Y. Akiyama, Kyoto University, Japan). Setting the 
threshold value at a minimum of 80% coherence to known consensus response elements, 49 putative 
transcription factors able to bind to the DNA sequence were identified. Putative transcription factor 
binding sites were identified to be present in different repetitions. Table 8 provides an overview of all 
the putative transcription factors identified and the number of their consensus motifs within the 2.8 kb. 
The transcription factors associated with the MAPK pathways (Sabio and Davis, 2014) are highlighted 
in Table 8. AP-1 is the only transcription factor that can be directly associated with p38 MAPK 
pathway, assuming that AP-1 is the down-steam target of p38 MAPK in the TNF-α mediated 
HSD17B3 promoter activation.  
Transcription 
factor 
binding site 
Number of 
repetitions 
Transcription 
factor 
binding site 
Number of 
repetitions 
CdxA  55 c-Ets-  4 
GATA-1  22 N-Myc  4 
SRY     17 SREBP-  3 
C/EBPβ 16 HNF-3b  3 
C/EBP 16 Sox-5   3 
Ik-2    15 Tst-1  3 
USF   13 c-Rel  2 
HSF2    10 c-Myc 2 
CREBP  10 E4BP4   2 
Evi-1   10 VBP     2 
AML-1a 9 HLF    2 
AP-1    9 Elk-1   1 
GATA-2  8 NRF-2   1 
GATA-3  8 Brn-2  1 
Nkx-2. 8 c-Myb   1 
MZF1   7 v-Myb 1 
Lyf-1 7 Pbx-1 1 
RORalp 6 STATx   1 
deltaE  6 MyoD    1 
S8      6 Tal-1a 1 
CREB   6 XFD-1   1 
HSF1  5 E2F     1 
GATA-X  5 CP2     1 
Oct-1 5 TATA    1 
HFH-2   5 
Table 8: Overview of the putative transcription factors that are able to bind to the 2.8 kb 
sequence of the HSD17B3 promoter analyzed. Transcription factors involved in the TNF-α signaling 
pathways are highlighted.  
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5.4.5 Discussion  
Steroid research in cancer, especially in PC predominately focuses on the AR, with respect to its 
expression, mode of action and inhibition (Miyahira et al., 2014). Although the AR is indisputably a 
very important player in the pathogenesis of cancer, upstream mechanisms determining the availability 
of AR ligands also need to be considered. In our study, we present novel data on HSD17B3 promoter 
activation, which may be important for understanding the dysregulation of androgen production in 
diseases characterized by chronic inflammation, such as cancer. We are the first to investigate the 
HSD17B3 promoter regulation. We constructed a Leydig cell model stably expressing a luciferase 
reporter under the control of the human HSD17B3 promoter. We used this cell line as a tool to identify 
compounds, which may activate the HSD17B3 promoter and subsequently enhance testosterone 
formation. We validated our new cell model with traditional, well-established methods such as RT-PCR 
and enzyme activity assays. The key finding of our study was the ability of TNF-α to induce the 
expression and activity of 17β-HSD3.  
TNF-α is a pleiotropic cytokine. It plays major roles in the pathogenesis of various diseases. TNF-α is 
mainly secreted by macrophages for sequential roles in inflammation (Manderson et al., 2007). 
Inflammation and inflammatory diseases, acute or chronic represent a heterogeneous group of 
conditions that can affect any organ or system (Sozzani et al., 2014). In many diseases, such as 
various autoimmune diseases, inflammatory processes represent cause and effect of the disease. 
However, in a wide variety of diseases, inflammation occurs subliminal as a second effect of the 
primary disease (Cox, 2012; Kaur, 2014). In such cases, chronic inflammation often develops, which 
propagates into overall systemic inflammation associated with co-morbidities. Inflammatory processes 
can promote or possibly even initiate malignant diseases (Balkwill et al., 2005). A recent review 
(Balkwill, 2006) summarizes the evidence for a link between cancer and inflammations. Many chronic 
diseases are associated with an increased risk of cancer. Cancers often arise at sites of chronic 
inflammation because of the increased presence of reactive oxygen and nitrogen species. Chemical 
mediators and nanoparticles (such as asbestos) are found in many cancers, and anti-inflammatory 
agents reduce the risk of mortality from some cancers (Balkwill et al., 2005; Balkwill and Mantovani, 
2001; Coussens and Werb, 2002). We suggest that HSD17B3 promoter dysregulation could have an 
impact on inflammation-mediated carcinogenesis and chronically inflamed tumors could contribute to 
higher testosterone levels indirectly through excessive secretion of TNF-α, which would in turn 
promote the growth of the tumor by AR activation.  
Furthermore, our observations may help to understand the development and progression of other 
forms of cancer in inflammatory diseases. In particular, the metabolic syndrome is well known for its 
underlying chronic inflammatory states (Trayhurn and Wood, 2004). In obesity, blood supply to 
adipocytes may be reduced, which may lead to hypoxia-induced cell damage and an overproduction 
of cytokines such as TNF-α or IL-6 (Cinti et al., 2005; Lau et al., 2005). Furthermore, adipocytes are 
known to independently express and secrete TNF-α. The prevalence of polycystic ovary syndrome, a 
metabolic disorder resulting in higher androgen levels, is markedly higher in obese women compared 
to woman of normal weight (Alvarez-Blasco et al., 2006), suggesting a relationship of inflammation 
and androgen levels. Adipocytes were identified early to act as an “endocrine organ” and to produce 
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steroids such as androgens (Siiteri, 1987). In premenopausal women, adipocytes contribute to the 
production of up to 50% of circulating testosterone (Belanger et al., 2002; Meseguer et al., 2002). It 
was shown, that different adipose tissues express 17β-HSD3. However, the total serum testosterone 
in obese men is lowered when compared to the levels of normal weight men. Additionally, testosterone 
treatment in obese man improved obesity parameters (body weight, waist circumference, and BMI) 
and lowered total cholesterol, LDL cholesterol, triglycerides, fasting blood glucose, HbA1c, and blood 
pressure in a 5-year study (Yassin et al., 2014). This discrepancy of higher androgen production within 
adipocytes and at the same time lowered systemic androgen levels is not yet fully understood and 
need to be studied further. However, it is known that the prevalence for multiple cancer types is 
elevated in obese populations (De Pergola and Silvestris, 2013). Prostate cancer also occurs more 
often in obese men compared to normal weight men (De Pergola and Silvestris, 2013). We suggest 
that the TNF-α-induced activation of the HSD17B3 promoter and subsequent up regulation of 
testosterone may play a role in the mechanisms by which obesity impacts on cancer development 
and/or progression.  
The establish links between cancer, inflammation and obesity are indisputable. In our study, we 
designed a novel tool, where mouse Leydig cells (MA-10 cells) derived from a Leydig cell tumor, stably 
expressed a luciferase reporter gene under control of a 2.8 kb sequence of the human HSD17B3 
promoter. Using this tool and combining it with assays in MA-10 cells and BLTK-1 Leydig mouse cells, 
which both endogenously express 17β-HSD3, we could demonstrate that the prototypic inflammatory 
cytokine TNF-α strongly activates the HSD17B3 promoter, which further leads to increased mRNA 
levels and enzymatic activity of 17β-HSD3. The HSD17B3-promoter activation suggests a novel 
pathway resulting in increased testosterone levels. We suggest that chronic inflammatory states, such 
as in cancer, may contribute to higher testosterone levels, which would in return promote growth of the 
tumor by AR activation. Moreover, other diseases states which chronic inflammation, such as the 
metabolic syndrome, could be adversely affected by higher androgen levels. Therefore, we 
investigated the pathway by which TNF-α exerts its action. We observed that the activation of the 
HSD17B3 promoter by TNF-α was mediated through the p38 MAPK and possibly the transcription 
factor AP-1. Another important finding of our study is that the TNF-α mediated action cannot be 
reversed by the potent and widely used anti-inflammatory agent dexamethasone. We are the first to 
suggest a pathway by which inflammation my directly lead to higher testosterone levels, which may 
contribute to the vicious circle of cancer progression, inflammation and elevated steroids level. 
With our study, we unveil several important observations which may contribute to the understanding of 
the mechanism underlying related inflammation, inflammation in adipocytes and altered testosterone 
levels.  
 
 
 
  
Project 3: Transcriptional regulation of 17β-HSD3 
75 
5.5 Outlook for part A: TNF-α dependent activation of 17β-
hydroxysteroid dehydrogenase type 3 promoter  
 
 Investigate the mechanism of TNF-α activation of p38 MAPK by inducing point mutations 
in the putative AP-1 consensus sequences within the promoter of HSD17B3 
The promoter analysis with the software TF-search suggests that p38 MAPK may activate AP-1. By 
point mutation of the putative AP-1 binding sites on the 2.8 kb promoter sequence, this hypothesis can 
be investigated. If TNF-α no longer is able to activate the mutated HSD17B3 promoter, it can be 
assumed that AP-1 is the nuclear factor responsible for the TNF-α-mediated activation. There were 9 
putative AP-1 binding sites predicted by the TFsearch, all of which may be involved. I propose to study 
first point mutations on the side closest to the start codon of the gene. In addition to its position, this 
site also showed the highest similarity to the putative AP-1 consensus binding sequence in the 
TFsearch.  
 Investigate the transcription factor involved in p38 MAPK downstream activation of the 
HSD17B3 promoter using CHIP-assays 
It is very unlikely that TNF-α, being known to provoke whole cascades of actions, only acts via one 
single nuclear factor. It can be expected, that a multitude of nuclear factors and/or nuclear receptors 
play a role in the TNF-α induced HSD17B3 promoter activation. Using Chromatin Immunoprecipitation 
(CHIP) assays we will try to identify proteins associated with the HSD17B3 promoter activation. 
 Measuring HSD17B3 mRNA levels in MA-10 cells at different time points 
The observation that the HSD17B3 promoter in MA-10 cells is activated and that the enzymatic activity 
of 17β-HSD3 is enhanced suggests that also the HSD17B3 mRNA of MA-10 cells is up regulated. 
However, we were so far not able to show such an up regulation in MA-10 cells. The mRNA is usually 
isolated 24 hours after the treatment. If the up regulation was transient and taking place very quickly 
after TNF-α incubation, it is possible that its expression levels reversed to normal after 24 hours. 
Shorter incubation time points will be tested (e.g. RNA isolation after 6 or 12 hours).  
 Verify the enhanced enzyme activity with mass spectrometry 
Although we showed in previous chapters that MA-10 cells produce testosterone as their predominant 
metabolite upon incubation with androstenedione, I suggest confirming the enhanced enzyme activity 
by LC-MS/MS. In addition, I also suggest measuring 17β-HSD3 enzyme activity after multiple time 
points (12 h, 24 h, and 48 h), since the stability of 17β-HSD3 protein has yet to be elucidated.  
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5.6 Focus Part B: Organotins activate the 17β-hydroxysteroid 
dehydrogenase type 3 promoter 
Organotins are very potent environmental toxins. Their toxicity manifests itself in very diverse organs 
and systems affecting a wide spectrum of species. Especially aquatic organisms suffer from organotin 
toxicity, since organotins persists in the water. We observed that organotins, especially tributyltin 
(TBT) and triphenyltin (TPT) result in an activation of the HSD17B3 promoter in the low nanomolar 
range. It is known that organotins can exert at least part of their action via the nuclear retinoid X 
receptor (RXR) (Grun and Blumberg, 2006; Nishikawa et al., 2004). If is further know, that organotins 
can cause imposex in mollusks. Imposex is a disorder caused by pollutants, such as organotins 
(Harrison et al., 2007), where affected female mollusks, develop male sex gonads, in addition to their 
female genital tract. Different pathways leading to imposex have been suggested. One of which 
involves RXR-signaling, since it was shown that 9-cis retinoic acid is able to promote imposex in sea 
shells (Nishikawa et al., 2004). We focused on the question, by which mechanism TBT and TPT exert 
their androgenic effects and whether the activation of the HSD17B3 promoter may provide an 
explanation for the research on organotin-mediated imposex.  
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5.7 Part B manuscript draft: 
Tributyltin- and triphenyltin-dependent up regulation of 17β- 
hydroxysteroid dehydrogenase 
5.7.1 Abstract 
Organotins exert a wide range of toxic effects. They were shown to act as endocrine disruptors in 
adipocytes as well as to cause reprotoxicity in both males and females in a variety of species. The 
molecular mechanism underlying theses effects are largely unknown. The organotins tributyltin (TBT) 
and triphenyltin (TPT) are known to induce imposex in female mollusks. Marine animals are 
predominately affected since organotins persist in aqueous environments. Female organisms affected 
by imposex develop male sex organs such as a penis, in addition to their fully developed female 
genital tract. The currently debated mechanisms by which imposex is driven include: high levels of 
testosterone, steroidogenic inhibition (to lower estrogen levels) and the activation of the nuclear 
receptor retinoid X receptor (RXR). Using a cell model stably expressing a luciferase reporter under 
the control of the promoter sequence of HSD17B3, the key enzyme in the androgen steroidogenesis 
catalyzing the formation of testosterone, we could show that TBT and TPT both potently up regulate 
the HSD17B3 promoter. The results demonstrate the pro-androgenic effects of TBT and TPT in a 
mouse/human Leydig cell system. Furthermore, we could show that the well characterized RXR 
ligand, 9-cis retinoic acid (9-cis RA), activates the HSD17B3 promoter. Our data provide evidence, that 
the TBT- and TPT-mediated up regulation of the HSD17B3 promoter is dependent on RXR activation. 
Future experiments need to test whether TBT- and TPT-dependent RXR activation also up regulates 
17β-HSD3 expression and activity in mollusks and fish and whether an enhanced 17β-HSD3 activity 
might play a role in the development of imposex in aquatic species.  
5.7.2 Introduction 
Organotin is a collective term for metal organic compounds containing one or more tin-carbon bonds. 
Their collective chemical formula is RnSnXm , where R refers to a carbon group, and X represents any 
other chemical group such as a halogen or hydroxyl group (Graf, 1996). The first organotin synthesis 
dates back to 1853 (Frankland, 1835). Until the 1990s, the worldwide annual production of organotins 
amounted to about 40‘000 tons. Three quarters of them were used as polyvinylchloride stabilizers. 
Other important applications included their use as biocides in anti-fouling coatings on ships to reduce 
encrustations by barnacles, algae, mussels, and other marine invertebrates (Choi et al., 2009) and as 
fungicides in agriculture (Graf, 1996). It took more than 100 years to figure out that the versatility of 
these chemicals is dramatically counterbalanced by its toxicity to biota (Appel, 2004; Fent, 1996; 
Nicholson, 1989). Goldberg and Maguire even stated that the organotin TBT is the most toxic 
substance that was ever deliberately introduced into the environment (Goldberg, 1986; Maguire, 
1987). One of the most surprising feature of organotin toxicity is the wide spectrum of responsive 
species, and the similarity of the responses in very different cell types and species (Pagliarani et al., 
2013). Organotin use today is restricted by law, but because of their harmful persistence in water 
environments (B. Eklund, 2008) , their continuous illegal use and their leaching from old paints make 
the organotins a persisting threat, even for future generations (Antizar-Ladislao, 2008; Fent, 1996). 
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The toxicological effects of organotins are wide-ranging and include reprotoxicity shown by a multitude 
of studies in male (Chen et al., 2008; Omura et al., 2001) and female rats (Grote et al., 2006; 
Harazono et al., 1996). Organotins also act as obesogenes (chemicals that promote obesity by 
increasing the number of fat cells or the storage of fat in existing fat cells (Grun and Blumberg, 2009; 
Grun and Blumberg, 2006)). According to the literature, these lipid changes are less pronounced (or 
perhaps less well understood) in invertebrates compared to vertebrates (Pagliarani et al., 2013). 
Exerting other toxic effects, organotins in particular are harmful to water-bound species, due to their 
persistence in water. During their early life, organisms are particularly sensitive to pollution and 
exposure can result in genital defects, abnormal gamete development, infertility or sex reversal 
(Jobling et al., 2002). A study in danio rerio (zebrafish) suggested, that fish exposed to TBT show a 
population with more males than the control group (McAllister and Kime, 2003). TBT was furthermore 
shown to induce imposex, the development of male sex organs in female snail, in addition to their 
complete female genital tract (Fent, 1996; Oberdorster and McClellan-Green, 2000; Smith, 1981). It is 
known, that organotins inhibit the aromatase (cytochrome P450 19A1) that converts testosterone into 
estradiol (Oberdorster and McClellan-Green, 2000) though it remains controversial whether the 
imposex phenomenon is predominately caused through this mechanism. Another hypothesis proposes 
the involvement of the RXR signaling pathway. It was shown that the organotins, TBT and TPT are 
potent agonists of the RXR (Grun and Blumberg, 2006; Nakanishi et al., 2005; Nishikawa et al., 2004). 
An injection of the RXR ligand 9 cis-retinoic acid into female snails induced imposex (Castro et al., 
2007; Horiguchi et al., 2008). These results strongly suggest the involvement of the RXR pathway in 
the development of imposex. Other mechanism have also been suggested such as whether increased 
testosterone levels caused by decreased metabolic clearance of testosterone leads to the 
development of imposex (Spooner N, 1991). This hypothesis is underlined by the observation that the 
AR agonist cyproterone acetate was able to inhibit imposex induction through TBT (Bettin, 1996).  
In the present study, we could show that the organotins TBT and TPT within a low nanomolar range 
potently activate the human promoter of HSD17B3, the key enzyme for the formation of testosterone 
in Leydig cells. The RXR ligand 9-cis retinoic acid also potently activated the promoter, which strongly 
suggested an involvement of the nuclear receptor RXR. We therefore propose that at least part of the 
organotin-mediated masculinization effects are mediated by RXR-dependent up regulation of 17β-
HSD3 and subsequent increase in testosterone synthesis. Since the mode of action in imposex 
formation is still debated, we further suggest that there might be a relationship between RXR signaling, 
elevated testosterone levels and the development of imposex.   
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5.7.3 Materials and Methods 
Cell culture  
The mouse Leydig cell clone MA-10C2, derived from the MA-10 cell line upon stably expressing a 
luciferase reporter under the control of a 2.8 kb sequence of the human HSD17B3 promoter (design 
described in chapters above) was cultivated as described previously for the MA-10 cells (Legeza et al., 
2013). Briefly, cells were grown on 0.1% gelatin-coated cell culture dishes in in DMEM/F12 medium 
(Invitrogen, Carlsbad, CA, USA) containing 20 mM HEPES (Gibco life technologies, Carlsbad, CA, 
USA ), 15% horse serum (Gibco life technologies), and 50 µg/ml gentamicin (Sigma-Aldrich, St. Louis, 
MO, USA) under standard conditions (5% CO2, 37°C). Organotins and 9-cis retinoic acid were 
obtained from Sigma-Aldrich at the highest grade available. 
HSD17B3 transactivation assay 
MA-10C2 cells were seeded on 24 well plates at a confluence of 60%, followed by incubation with 
medium containg TBT, TPT or 9-cis RA at the desired concentrations (500 pm, 1 nM, 10 nM, 50 nM 
for TBT; 1 nM, 10 nM, 50 nM for TPT and 10 µM for 9-cis RA) for 24 hours at standard conditions 
(37°C, 5% CO2). After incubation, cells were washed with phosphate buffered saline (PBS), lysed with 
Tropix lysis buffer (Applied Biosystems, Foster City, CA) supplemented with 0.5 mM dithiothreitol, and 
frozen at -80°C following 10 minutes incubation at room temperature. Lysates were analyzed for 
luciferase activity at 470 nM on a Spectramex L (Molecular Devices, Sunnyvale, CA, USA ) using a 
luciferine-solution (Rebuffat et al., 2004). Levels were normalized to DMSO control treatments.  
Statistical analysis 
Data are expressed as the mean ± standard deviation (S.D.) of at least three independent 
experiments. The significance of differences within the data was assessed by one-way analysis of 
variance (ANOVA), with Tukey post-test for multiple comparisons.  
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5.7.4 Results 
Induction of the HSD17B3 promoter by TBT and TPT 
To investigate whether TBT and TPT activate the HSD17B3 promoter within environmentally relevant, 
low nanomolar concentrations, we treated MA-10C2 cells with increasing concentrations of TBT 
(Figure 20A) and TPT (Figure 20B). TBT and TPT both dose-dependently activated the HSD17B3 
promoter, however, TBT showed a more potent effect with promoter activation detected at 
concentrations as low as 500 pm. 
    A             B 
 
 
 
 
 
 
 
Figure 20: TBT and TPT potently activate the HSD17B3 promoter. In MA-10C2 cells treated for 24 
h with TBT at 500 pm, 1 nM, 10 nM and 50 nM or TPT at 1 nm, 10 nM and 50 nM, a dose dependent 
activation of the HSD17B3 promoter was observed. The data represent the mean ± S.D. of three 
independent experiments. ***p ≤ 0.001, **p ≤ 0.01. 
Induction of the HSD17B3 promoter by the RXR ligand 9-cis retinoic acid 
To underline our hypothesis that the organotins tested act via RXR, we tested whether 9-cis RA 
activates the HSD17B3 promoter. We observed a threefold increase in the HSD17B3 promoter 
activation upon incubation with 9-cis RA (Figure 21), which is an endogenous RXR ligand in humans. 
 
 
 
 
 
Figure 21: The endogenous RXR ligand 9-cis RA, 
activates the HSD17B3 promoter In MA-10C2 cells treated 
with 10 µM 9-cis RA for 24 h, a significant activation of the 
HSD17B3 promoter was observed The data represent the 
mean ± S.D. of three independent experiments.***p ≤ 0.001. 
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5.7.5 Discussion  
It has been shown that organotin-induced disturbances (especially due to TBT and TPT exposure), 
such as imposex or lipid dysbalance are mediated by RXR pathways (Castro et al., 2007; Grun and 
Blumberg, 2006; Nakanishi et al., 2005; Nishikawa et al., 2004). Previous reports implicated 
aromatase inhibition in the development of imposex (Bettin, 1996; Spooner N, 1991). Based on further 
observations, it was concluded that higher testosterone levels due to inhibition of its degradation might 
lead to the development of imposex (Spooner N, 1991), or that imposex develops due to an imbalance 
of testosterone and estradiol (Schulte-Oehlmann et al., 1995). In a recent review based in on all 
available data on imposex, the authors selected key experiments, which they repeated and they 
designed new experiments which supported the theory of RXR pathway involvement in imposex 
(Stange et al., 2012). It was shown that TBT, HX630, a RXR agonist designed by Umemiya (Umemiya 
et al., 1997), but not 9-cis RA, were able to induce imposex in the marine snail Nucella lapillus. The 
AR antagonist cyproterone acetate led to a suppression of TBT-induced imposex, while the RXR 
antagonist HX531 (Umemiya et al., 1997) could not antagonize TBT effects (Stange et al., 2012). 
Strange et al. concluded that aromatase inhibition and RXR signalling pathways may be cross 
interacting in the development of imposex. In another recent study, RXR isoforms from the sea snail 
Thais clavigera were cloned and expressed in a mammalian cell line (Urushitani et al., 2011). 
Transcriptional activation of the isoform TC-RXR-1 was observed following treatment with 9-cis RA, 
TBT-Cl and TPT-Cl. However, cis-docosahexaenoic acid, an RXR activator in vertebrates (de Urquiza 
et al., 2000), did not activate RXR isoforms. RXR gene transcription in different tissues of Nucella 
lapillus was studied by Lima et.al (Lima et al., 2011). They observed that RXR transcription was down 
regulated in the central nervous system of females before and after imposex initiation by TBT. Higher 
transcription levels were observed in the male penis and the penis of females affected by imposex. 
Lima et al. suggested that different RXR signalling pathways are influenced by TBT. The action of 
RXR cannot be described conclusively, since RXR, depending on its dimerization partner and its 
ligand, can act as repressor or as co-activator. Upon dimerizing with the AR, RXR can either act as a 
repressor following the binding of 9-cis RA or as co-activator when unbound (Chuang et al., 2005). 
RXR can furthermore form heterodimers with various nuclear receptors, e.g. RAR, thyroid hormone 
receptors or vitamin D receptors (Gronemeyer et al., 2004). The existing data is partly conflicting since 
an activation of RXR by a synthetic agonist resulted in imposex formation, whilst a synthetic antagonist 
of RXR did not prevent imposex development (Stange et al., 2012). 
In summary, the mechanisms leading to imposex are not yet fully understood, but the available data 
strongly suggest that RXR signalling is involved. We hypothesize that RXR signalling plays an 
important role in the activation of the HSD17B3 promoter. HSD17B3 is a gene that has not been 
considered yet in previous studies of imposex. We show that the HSD117B3 promoter is up regulated 
by nanomolar concentrations of TBT and TPT, which could possibly lead to higher expression of 17β-
HSD3 in vivo and therefore, may result in elevated testosterone levels. Elevated testosterone levels 
may contribute to the development of imposex, as suggested by Spooner et al. in 1991 (Spooner N, 
1991). We further suggest, that the organotin mediated activation of the HSD17B3 promoter might be 
an important mechanism involved in androgen disruption and masculinisation in animals affected by 
disorders of sexual development caused by organotins.    
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5.8 Outlook for Part B: Tributyltin- and triphenyltin-dependent up 
regulation of 17β-hydroxysteroid dehydrogenase 
The above findings strongly suggest that RXR is involved in the mechanism of HSD17B3 promoter up 
regulation. Elevated testosterone levels and RXR mediated signaling may play a role within the 
development of imposex. I suggest conducting further experiments to support this hypothesis.  
 Measure 17BHSD3 mRNA levels in tissues from TBT-or TPT-exposed animals 
HSD17B3 levels are a key measure of our hypothesis. Tissues of relevant animal models (snails) 
exposed to TBT or TPT should be analyzed by RT-PCR for elevated HSD17B3 levels. Since it is a 
mechanistic study, other animal models (e.g. mice) may also be used.  
 Analyze the HSD17B3 promoter for potential RXR binding sites with Nubiscan, followed 
by point mutations for functional confirmation 
Gaining further evidence for the involvement of RXR could be achieved by the analysis of the 2.8 kb 
sequence for putative nuclear receptor binding sites. I suggest using the in silico tool Nubiscan 
(designed by M. Podvinec, University of Basel, Basel) for such an analysis. Once putative RXR 
binding sites are identified, the functional relevance of these sites could be tested by deletions or 
point mutations.  
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